Advertisement

Psychodysleptica

  • Thomas Geschwinde
Chapter

Zusammenfassung

Vorbemerkung: Die Zusammenfassung psychotroperStoffe unterschiedlichster chemischer Struktur und Anwendungsformen unter Oberbegriffen erfolgt in diesem Buch in erster Linie im Hinblick auf vergleichbare durch sie ausgelöste psychische Wirkungen.

Literatur

  1. Abel EL (1971) Marihuana and memory acquisition or retrieval? Sci 173:1038–1040CrossRefGoogle Scholar
  2. Abel EL (1976) The scientific study of marihuana. Hall, ChikagoGoogle Scholar
  3. Abelson PH (1968) LSD and marihuana. Sci 159:89–97Google Scholar
  4. Aberle D (1966) The Peyote religion among the Navaho. Aldine, ChikagoGoogle Scholar
  5. Ablon SL, Goodwin FK (1974) High frequency of dysphoric reactions to tetrahydrocannabinol among depressed patients. Am J Psychiatry 131:448–453CrossRefGoogle Scholar
  6. Abood LG, Biel JH (1962) Anticholinerge Psychotomimetica. Int Rev Neurobiol 4:217–273CrossRefGoogle Scholar
  7. Adamowicz P, Gieron J (2016) Acute intoxication of four individuals following use of the synthetic cannabinoid MAB-CHMINACA. Clin Toxicol 54(8):650–654CrossRefGoogle Scholar
  8. Adams AJ et al (1975) Alcohol and marihuana effects on static visual acuity. Am J Ophthalmol 52:729–735Google Scholar
  9. Agosti V, Nunes E, Levin F (2002) Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence. Am J Drug Alcohol Abuse 28:643–652CrossRefGoogle Scholar
  10. Agurell S et al (1971) Metabolism of 7-hydroxy-delta-1-(16)-THC and CBN. Acta Pharm Suec 8Google Scholar
  11. Agurell S, Gustafson B, Holmstedt B (1973) Quantitation of Δ1-tetrahydrocannabinol in plasma from cannabis smokers. J Pharm Pharmacol 25:448–554CrossRefGoogle Scholar
  12. Agurell S, Dewey WL, Willette RE (eds) (1984) The cannabinoids: chemical, pharmacologic and therapeutic aspects. Academic Press, New YorkGoogle Scholar
  13. Agurell S, Halldin M, Lindgren JE et al (1986) Pharmacokinetics and metabolism of delta 1-tet rahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38:21–43Google Scholar
  14. Ahmedzai S, Carlyle DL, Calder IT, Moran F (1983) Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Brit J Cancer 46(5):657–663CrossRefGoogle Scholar
  15. Akinloye BA, Court WE (1981) The alkaloids of Rauwolfia volsinii. J Etnopharmacol 4:99–109CrossRefGoogle Scholar
  16. Albertson DN, Grubbs LE (2009) Subjektive effects of Salvia divinorum: LSD- or mariju-ana-like? J Psychoactive Drugs 41:213–217CrossRefGoogle Scholar
  17. Algeier-Föll R (1991) Cannabis und Verkehrstauglichkeit (Literaturüberblick). Zentralbl Rechtsmed 35:614–623Google Scholar
  18. Alpert R (1969) Psychedelics and sexual behavior. J Sex Res 5:50–54CrossRefGoogle Scholar
  19. Alt A, Reinhardt G (1996) Speiseöle auf Hanfbasis und ihr Einfluß auf die Ergebnisse von Urinund Blutanalysen. Blutalkohol 33:347–356Google Scholar
  20. Alt A, Reinhardt G (1997) Nahrungsmittel auf Hanfbasis und deren forensische Bedeutung. Blutalkohol 34:286–293Google Scholar
  21. Ambrose JB, Bennett HD, Lee HS, Josephson SA (2010) Cerebral vaculopathy after 4-bromo-2,5-dimethoxyphenethylamine ingestion. Neurologie 16(3):199–202CrossRefGoogle Scholar
  22. Amendt G (1974) Haschisch und Sexualität. Enke, StuttgartGoogle Scholar
  23. Anderson EF (1969) The biogeography, ecology, and taxonomy of lophophora (cactacea). Brittonia 21(4):229–310CrossRefGoogle Scholar
  24. Andersson PG (1975) Ergotamine headache. Headache 15:118–121CrossRefGoogle Scholar
  25. Andréasson S, Engström A, Allebeck P, Rydberg U (1988) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 11:1483–1486Google Scholar
  26. Andrews G, Vinkenoog S (eds) (1968) The book of grass. Grove, New YorkGoogle Scholar
  27. Angst J (1970) Halluzinogen-Abusus. Schweiz Med Wochenschr 100:710–715Google Scholar
  28. Angst J, Dittrich A, Woggon B (1972) Psychologische und klinische Aspekte des Cannabismißbrauchs. Z Allgemeinmed 48:94–99Google Scholar
  29. Anonymus (1981) Cannabis im Garten. Volksverlag, LindenGoogle Scholar
  30. Appel J, Kim-Appel D (2007) The rise of a new psychoaktive agent: Savia divinorum. Int J Mental Health Addiction 5:248–253CrossRefGoogle Scholar
  31. Ashton CH (1999) Adverse effcts of cannabis and cannabinoids. Br J Aneasthesia 83(4):637–649CrossRefGoogle Scholar
  32. Ashton CH (2001) Pharmacology and effects of cannabinoids: a brief review. Br J Psychiat 178:101–106CrossRefGoogle Scholar
  33. Atwood BK, Huffman J, Straiker A, Mackie K (2010) JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB1 receptor agonist. Br J Pharmacol 160(3):585–593CrossRefGoogle Scholar
  34. Atwood BK, Lee D, Straiker A, Widlanski TS, Mackie K (2011) CP47,497-C8 and JWH-073, commonly found in ‘Spice’ herbal blends, are potent and efficacious CB1 cannabinoid receptor agonists. Eur J Pharmacol 659(2–3):139–145CrossRefGoogle Scholar
  35. Auwärter V et al (2009) Sice an other herbal blends:harmless incense or cannabinoid designer drugs?. J of Mass Spectrom 55(5):832–837CrossRefGoogle Scholar
  36. Auwärter V, Kneisel S, Hutter M, Thierauf A (2012) Synthetische Cannabinoide – Forensische Relevanz und Interpretation analytischer Befunde. Rechtsmedizin 22(4):258–271CrossRefGoogle Scholar
  37. Babu KM, McCurdy CR, Boyer EW (2008) Opiod receptors and legal highs: salvia divinorum and kratom. Clin Toxicol (Philadelphia) 46(2):146–152CrossRefGoogle Scholar
  38. Bachmann EW, Hoffmann AA, Waser PG (1979) Identification of Δ9-tetrahydrocannabinol in human plasma by gas chromatography. J Chrom 178:320–323CrossRefGoogle Scholar
  39. Bailey DN (1979) Phencyclidine abuse. Am Clin Pathol 72:759Google Scholar
  40. Baker AA, Lukas EG (1969) Some hospital admissions associated with cannabis. Lancet 1:148–160CrossRefGoogle Scholar
  41. Baldrigde EB, Bessen HA (1990) Phencyclidine. Emegency Medicine Clinics of North America 8(3):541–550Google Scholar
  42. Balmelli C, Kupferschmidt H, Rentsch M et al (2001) Fatal brain edema after ingestion of ecstasy and benzylpiperazine. M Dtsch Med Wochenschr 126(28–29):809–811CrossRefGoogle Scholar
  43. Balster RL, Chait LD(1976) The behavioral pharmakology of phencyclidine. Clin Toxicol 9(4):573–578CrossRefGoogle Scholar
  44. Barnes C, Fried PA (1974) Tolerance to delta-9-THC in adult rats with differential delta-9-THC exposure with immature or during early adulthood. Psychopharmacol (Berlin) 34:181–190CrossRefGoogle Scholar
  45. Battegay R, Bäumler J, Gnirss F, Ladewig D (1969) Zur Drogenabhängigkeit vom Typ Cannabis (Haschisch, Marihuana). Schweiz Med Wochenschr 99:965–971Google Scholar
  46. Battersby AR (1963) Recent researches on indole alkaloids. Pure Appl Chem 6:471–488CrossRefGoogle Scholar
  47. Bauer W (Hrsg.) (1980) Fliegenpilz – Fleisch der Götter. Schamanistische Ekstasekulte in Europa. Trikont, MünchenGoogle Scholar
  48. Baumann MH, Clark RD, Budzynski AG et al. (2004) Effects auf „Legal X“ piperazine analogs on dopamine and serotonin relaese in rat brain. Annals of the New York Academy of Sciences 1025:189–197CrossRefGoogle Scholar
  49. Baumann MH, Clark RD, Budzynski AG et al. (2005) N-substituted piperazines abused by humans mimic the molecular mechanismem of 3,4-Methylendioxymethamphetamine (MDMA or „Ecstasy“). Neuropsychopharmacol 30(3):550–560CrossRefGoogle Scholar
  50. Baumgartner AM, Jones PF, Black CT (1981) Detection of phencyclidine in hair. J Forensic Sci 26:576–581CrossRefGoogle Scholar
  51. Baumgartner WA (1986) Analysis of tetrahydrocannabinol (THC) in hair. US Navy Rehabilitation Center Study, Final Report pp 1–16Google Scholar
  52. Beaubrun MH, Knight F (1973) Psychiatric assessment of 30 chronic users of cannabis and 30 matched controls. Am J Psychiatry 130: 309–311CrossRefGoogle Scholar
  53. Beautrais AL et al (1999) Cannabus abuse and serious suicide attempts. Addiction 94(8):1155–1164CrossRefGoogle Scholar
  54. Beck O, Helander A, Karlson-Stiber C et al (1998) Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: possible role in adverse reactions. J Analyt Toxicol 22(1):45–49CrossRefGoogle Scholar
  55. Behr H-G (oJ) Haschisch-Kochbuch. Volksverlag, LindenGoogle Scholar
  56. Behr H-G (1982) Von Hanf ist die Rede. Sphinx, BaselGoogle Scholar
  57. Below E, Rosenstock S, Lignitz E (2005) Hanfprodukte auf dem deutschen Lebensmittelmarkt. THC-Gehalt und forensische Bedeutung. Blutalkohol 42:442–449Google Scholar
  58. Benecke M (1997) TECHNO – Eine verwirrende Partykultur. Kriminalistik 7:475–479Google Scholar
  59. Benitez F (1968) En la tierra màgica del peyote. Biblioteca Era, Serie Popular, MexikoGoogle Scholar
  60. Benschop A, Rabes M, Korf DJ (2002) Pille testing: Ecstasy and Prevention. Rozenberg, AmsterdamGoogle Scholar
  61. Berghaus G, Meininger I (Hrsg.) (1998) Cannabis im Straßenverkehr. Gustav-Fischer, Stuttgart, Jena, Lübeck, UlmGoogle Scholar
  62. Berhardson G, Gunne LM (1972) 46 cases of psychoses in cannabis abusers. Int J Addict 7:9–16CrossRefGoogle Scholar
  63. Beringer K (1927) Der Meskalinrausch. Springer, Berlin (Neudruck 1969)CrossRefGoogle Scholar
  64. Beringer K (1932) Zur Klinik des Haschischrausches. Nervenarzt 5: 30–41Google Scholar
  65. Berkefeldt K, Löhrer F (1998) Biogene Drogen. Kriminalistik 8–9: 563–566Google Scholar
  66. Betz P, Janzen J, Roider G et al (1991) Psychopathologische Befunde nach Aufnahme von Inhaltsstoffen heimischer Nachtschattengewächse. Archiv f Kriminol 188:175–182Google Scholar
  67. Bialos DS (1970) Adverse marijuana reactions: A critical examination of the literature with selected cas material. Am J Psychiatry 127:819–823CrossRefGoogle Scholar
  68. Binder MA (1981) Haschisch und Marihuana – was der Arzt über Cannabinoide wissen sollte. Dtsch Ärztebl 78:117–120Google Scholar
  69. Bischoff WH (1966) The exstasy drugs. Univ Circle Press, Delray BeachGoogle Scholar
  70. Blaine JD, Meacham MP, Janowsky DS, Schoor M, Bozetti LP (1976) Pharmacology of marijuana. Raven, New YorkGoogle Scholar
  71. Blevins D, Regan JD (1976) Delta-9-THC. Effect an macromolecular synthesis in human and other mammalian cells. In: Nahas GG, Paton WOM, Idänpää-Heikkilä JF (eds) Marihuana: Chemistry, biochemistry, and cellular effects. Springer, New York, pp 32–68Google Scholar
  72. de Boer D, Bosman IJ, Hidvegi E et al (2001) Piperazine-like compounds; a new gropu of designer drugs-of-abuse on the European market. Forensic Sci Intern 121:47–56CrossRefGoogle Scholar
  73. Boettcher C (1866) Über die Anwendung des indischen Hanfes in der Psychiatrie. Berl Klin Wochenschr 3Google Scholar
  74. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL (2002) Dose-related neurocognitive effects of marijuana use. Neurology 59:1337–1343CrossRefGoogle Scholar
  75. Bonnie RJ, Whitebread CH (1978) The marihuana conviction. Univ Press of Virginia, CharlottesvilleGoogle Scholar
  76. Bonnet U, Mahler H (2015) Synthetische Camnnabinoide: Verbreitung, Suchtbiologie und aktuelle Perspektive der persönlichen Suchtgefährdung. Fortschr Neurol Psychiatr 83(4):221–231CrossRefGoogle Scholar
  77. Bogusz M, Schmidt G (1990) Forensisch-toxikologische Aspekte des Cannabis-Missbrauchs. Zbl Rechtsmed 33:383–398Google Scholar
  78. Borg J, Gershon S, Alpert M (1975) Dose effects of smoked marihuana on human cognitive and motor function. Psychopharmacol 42:211–218CrossRefGoogle Scholar
  79. Boroffca A (1978) Cannabis und Psychiatrie. Suchtgefahren 24:28–37Google Scholar
  80. Borschke B (2002) Salvia Divinorum und andere psychoaktive Salbeiarten. Grüne KraftGoogle Scholar
  81. Bossong MG, Van Dijk JP, Niesink RJM (2005) Methylone and mCPP, two new drugs of abuse? Addic Biol 10:321–323CrossRefGoogle Scholar
  82. Bosmann U, Lusthof KJ (2003) Forensic cases involving the use of GHB in the Netherlands. Forensic Sci Int 133:17–21CrossRefGoogle Scholar
  83. Bossong MG, Van Dijk JP, Niesink RJM (2005) Methylone and mCPP, two new drugs of abuse? Addiction Biology 10:321–323CrossRefGoogle Scholar
  84. Bost RO (1988) 3,4-Methylendioxymethamphetamine (MDMA) and other Amphetamine Derivats. J Forensic Sci 33(2):576–587CrossRefGoogle Scholar
  85. Bové FJ (1970) The story of Ergot. Karger, BaselGoogle Scholar
  86. Bovens MG, Hansjakob T (2002) Rechtliche Neuregelung von halluzinogenen Pilzen. Kriminalistik 7:471–477Google Scholar
  87. Bowen JS, Davis GB, Kearney TE, Bardin J (1983) Diffuse vascular spasm associated with 4-bromo-2,5-dimethoxyamphetamine ingestion. JAMA 249(11):1477–1479CrossRefGoogle Scholar
  88. Bowman M, Pihl R (1973) Cannabis: Psychiological effects of chronic heavy use. Psychopharmacol (Berlin) 29:159–170CrossRefGoogle Scholar
  89. Braida D, Capurro V, Zani A et al (2009) Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents. Brit J Pharmavol 157:844–853CrossRefGoogle Scholar
  90. Braida D, Limonta V, Capurro V et al (2008) Involvement of κ-opioid and endocannabinoid system on savinorin A-induced reward. Biolog Psychiatry 63:286–292CrossRefGoogle Scholar
  91. Bram S, Bracet P (1976) Inhibition of proliferation and differentation of D. dicoideum amoebae by THC and cannabinol. In: Nahas GG, Paton WOM, Idänpää-Heikkilä JF (eds) Marihuna: Chemistry, biochemistry, and cellular effects. Springer, New York, pp 116–138Google Scholar
  92. Bratzke H, Klug E (1985) Gewaltdelikte und LSD-Rausch. Beitr gerichtl Med 43:179–186Google Scholar
  93. Braude MC, Szara S (eds) (1976) Pharmacology of marihuana. Raven, New YorkGoogle Scholar
  94. Brawley P et al (1972) Pharmacology of hallucinogens. Pharmacol Rev 24Google Scholar
  95. Brecher M, Wang BW, Wong H, Morgan JP (1988) Phencyclidine and violence: clinical and legal issues. J Clin Psychopharmacol 8(6):397–401CrossRefGoogle Scholar
  96. Bredt BM, Higuera-Alhino D, Shade SB, Hebert SJ et al (2002) Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol 42(11 Suppl):82–89CrossRefGoogle Scholar
  97. Bremkamp S (1980) PCP: Learning to like a dangerous drug. J Psychedelic Drugs 12(2):171–172CrossRefGoogle Scholar
  98. Brenneisen R, Egli A, Elsohly MA, Henn V, Spiess Y (1996) The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 34:446–452Google Scholar
  99. Brickenstein R (1971) Gefahren der Cannabisdrogen für Heranwachsende. Z Allgemeinmed 47:846–851Google Scholar
  100. Bromberg W (1934) Marihuana intoxication. Am J Psychiatry 91:303–340CrossRefGoogle Scholar
  101. Bromberger A, Goerke R, Weinmann W (1999) Bestimmungsgrenzen für den Nachweis von Cannabinoiden im Serum. Rechtsmed 9:131–137CrossRefGoogle Scholar
  102. Bron B (1979) Psychopathologisches Erscheinungsbild und klinische Bedeutung des Horror-Trips. Suchtgefahren 25(4):167–176Google Scholar
  103. Bron B (1987) Drogeninduzierte Intoxikationen und Psychosen. Fortschr Med 4:73–76 und 5:94–96Google Scholar
  104. Brown FC (1972) Halluzinogenic drugs. Thomas, Springfield/IlGoogle Scholar
  105. Brunner TF (1977) Marijuana in Ancient Greece and Rome? J Psychedelic Drugs 9(3):221–225CrossRefGoogle Scholar
  106. Bschor F (1950) Marihuana. Kriminalistik 4:19–24Google Scholar
  107. Budney AJ, Novy PL, Hughes JR (1999) Marijuana withdrawl among adults seeking treatment for marijuana dependence. Addiction 94:1311–1321CrossRefGoogle Scholar
  108. Bull J (1971) Cerebral atrophy in young Cannabis smokers. Lancet 11:1420–1448CrossRefGoogle Scholar
  109. Bundesinstitut für gesundheitlichen Verbraucherschutz und Veterinärmedizin (2000) BgVV empfiehlt Richtwerte für THC (Tetrahydrocannabinol) in hanfhaltigen Lebensmitteln. BgVV Pressedienst 07/2000 vom 16.3.2000Google Scholar
  110. Burns RS, Lerner SE (1976) Phencyclidine: An emerging drug problem. Clin Toxicol 9(4):473–475CrossRefGoogle Scholar
  111. Burns RS et al (1978) Cause of PCP-related death. Clin Toxicol 12(4): 463CrossRefGoogle Scholar
  112. Burroughs W, Ginsberg A (1964) Auf der Suche nach Yagé. Limes, WiesbadenGoogle Scholar
  113. Burstein S, Kupfer D (1971) Hydroxylation of trans-delta-l-THC by hepatic microsomal oxygenase. Ann NY Acad Sci 191:32–37CrossRefGoogle Scholar
  114. Butler JL, Gaines LS, Lenox JR (1976) Effects of marijuana expectation and suggestibility an cognitive functioning. Percept Mot Skills 42:1059–1065CrossRefGoogle Scholar
  115. Bye RA Jr (1979) Hallucinogenic plants of the tarahumara. J Ethnopharmacol 1:23–48CrossRefGoogle Scholar
  116. Caldwelle DF et al (1969) Auditory and visual threshold effects of marihuana in man. Percept Mot Skills 29:755–759CrossRefGoogle Scholar
  117. Callaway CA, Johnson MP, Gold LH, Nichols DE, Geyer MA (1991) Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists. Psychopharmacol 104(3):293–302CrossRefGoogle Scholar
  118. Callaway CA, Geyer MA (1992) Stimulant effects of 3,4-methylendioxymethamphetamine in the nucleus accumbens of rat. Eur J Pharmacol 214(1):45–51CrossRefGoogle Scholar
  119. Campbell AMG, Evans M, Thomson JLG, Williams MJ (1971) Cerebral atrophy in young cannabis smokers. Leancet 11:1219–1224CrossRefGoogle Scholar
  120. Campbell AMG, Evans M, Thomson JLG, Williams MJ (1972) Cerebral atrophy in young cannabis smokers. Lancet 1:202 ffCrossRefGoogle Scholar
  121. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Br Med J 323:13–16CrossRefGoogle Scholar
  122. Carlezon WA Jr, Béguin C, Knoll AT et al (2009) Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol Therapeutics 123:334–342CrossRefGoogle Scholar
  123. Carlin AS, Post RD (1971) Patterns of Drug Use Among Marihuna Smokers. JAMA 218:867–868CrossRefGoogle Scholar
  124. Carlin AS, Trupin EW (1977) The effect of long-term chronic marijuana use on neuropsychological functioning. Int J Addict 12:36–48CrossRefGoogle Scholar
  125. Carlin AS et al (1972) Social facilitation of marihuana intoxication. J Abnorm Psychol 80:132–140CrossRefGoogle Scholar
  126. Carlson KA (1979) PCP from the other side. J Psychedelic Drugs 11(3): 231–238CrossRefGoogle Scholar
  127. Cashman J (1968) LSD, die Wunderdroge. Ullstein, Frankfurt am MainGoogle Scholar
  128. Casswell M (1975) Cannabis and temporal desintegration on experienced and naive subjects. Sci 179:803–805CrossRefGoogle Scholar
  129. Castillo JD, Anderson M, Rubboton GM (1975) Marijuana, Absinthe and the Central Nervous System. Nat 253:365–366CrossRefGoogle Scholar
  130. Casto D (1970) Marijuana and the assassins, an etymological investigation. Br J Addict 65:219–225CrossRefGoogle Scholar
  131. Carter N, Rutty GN, Milroy CM, Forrest ARW (2000) Deaths associated with MBDB misuse. J Legal Med 113:168–170CrossRefGoogle Scholar
  132. Cervantes J, Clarke RC (1993) Marihuana drinnen. Alles über den Anbau im Haus. Sensi Seeds, AnsterdamGoogle Scholar
  133. Chait LD, Fischman MW, Schuster CR (1985) „Hangover“ effects the morning after marijuana smoking. Drug Alcohol Depend 15:229–238CrossRefGoogle Scholar
  134. Chan GC, Hinds TR, Impey S, Storm DR (1998) Hippocampal neurotoxicity of δ 9-te trahydrocannabinol. J Neurosci 18:5322–5332CrossRefGoogle Scholar
  135. Chatterjee A (1953) Rauwolfia alkaloids. Fortschr Chem Organ Naturst 10:390–394Google Scholar
  136. Chavalampous KD, Walker KE, Kinross-Wright J (1966) Metabolic fate of mescaline in man. Psychopharm 9:48–63CrossRefGoogle Scholar
  137. Chavkin C, Sud S, Jin W et al (2004) Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious κ-opioid receptor agonist: structural and functional considerations. J Pharmacol Experimen Therapeutics 308:1197–1203CrossRefGoogle Scholar
  138. Cherniak L (1979) The great books of hashish. And/Or Press, BerkeleyGoogle Scholar
  139. Chiang C-W, Barnett G (1984) Marijuana effect and delta-9-tetrahydrocannabinol plasma level. Clin Pharmacol Ther 36:234–238CrossRefGoogle Scholar
  140. Childers SR et al (1994) Effects of Amandamide on Cannabinoid Receptors in Rat Brain Membrane. Biochem Pharmacol 47:711–714CrossRefGoogle Scholar
  141. Chopra GS (1973) Studies an psycho-clinical aspects of long-term marihuana use in 124 cases. Int J Addict 8:1015–1026CrossRefGoogle Scholar
  142. Clark LD, Nakashima EN (1968) Experimental stufies of marihuana. Am J Psychiatry 125:379–384CrossRefGoogle Scholar
  143. Claussen U, Korte F (1966) Herkunft, Wirkung und Synthese der Inhaltsstoffe des Haschisch. Naturwissenschaften 21:541–546CrossRefGoogle Scholar
  144. Co BT, Goodwin DW, Gado M, Mikhael M, Hill SY (1977) Absence of cerebral atrophy in chronic cannabis users. JAMA 237(12):1229–1230CrossRefGoogle Scholar
  145. Cohen S (1965) The beyond within – The LSD story. Atheneum, New YorkGoogle Scholar
  146. Cohen S (1966) A classification of LSD complications. Psychosomatics 7:182–186CrossRefGoogle Scholar
  147. Cohen S (1967) Psychotomimetics agents. Ann Rev Pharm 7:301–318CrossRefGoogle Scholar
  148. Cohen S (1982) Cannabis and sex: Multifacted paradoxes. J Psychedelic Drugs 14(1–2):55–58CrossRefGoogle Scholar
  149. Colbach E (1971) Marijuana use by GI’s in Vietnam. Am J Psychiatry 128:204–207CrossRefGoogle Scholar
  150. Coleman JH, Tacker HL, Evans WE, Lemmi H, Britton EL (1976) Neurological manifestations of chronic marihuana intoxication. Part 1: Paresis of the fourth cranial nerve. Dis Nerv Syst 37:29–38Google Scholar
  151. Collins M (2011) some new psychoactive substance precursor chemicals and synthesis-driven endproducts. Drug Testing and Analysis 3(7–8):404–416CrossRefGoogle Scholar
  152. Compton DR et al (1992) Pharmacological profile of series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J of Pharmacol and Experim Therapeutics 260(1):201–209Google Scholar
  153. Compton DR et al (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J of Pharmacol and Experim Therapeutics 265(1):218Google Scholar
  154. O’Connor JE, Rejent TA (1981) EMIT cannabinoid assay: confirmation by RIA und GC/MS. J Anal Tox 6:168–173CrossRefGoogle Scholar
  155. Conrad B III (1988) Absinthe: History in a Bottle. Chronicle Books, San FranciscoGoogle Scholar
  156. Consroe PF, Man DP (1973) Effects of Δ8- and Δ9-tetrahydrocannabinol on experimental induced seizures. Life Sci 13:429–439CrossRefGoogle Scholar
  157. Cooper R (1978) A guide to British psilocybin mushrooms. Hassle Free PressGoogle Scholar
  158. Couper F, Logan BK (2000) Determination of γ-Hydroxybutyrate (GHB) in biological specimens by gas chromatograohy-mass spectrometry. J Anal Toxicol 24:1–7CrossRefGoogle Scholar
  159. Crawford WJ, Merritt JC (1979) Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharmacol Biopharm 17:191–196Google Scholar
  160. Croft RJ, Mackay AJ, Mills ATD, Gruzelier JGH (2001) The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacol 153:373–379CrossRefGoogle Scholar
  161. Crowley TJ, Macdonald MJ, Whitmore E, Mikulich SK (1998) Cannabis dependence, withdrawel, and re-inforcement effects among adolescents with conduct symptoms and substance use disorders. Drug Alcohol Depend 50:27–37CrossRefGoogle Scholar
  162. Croxford JL (2003) Therapeutic potential of cannabinoids in CNS disease. CNS-Drugs 17(3):179–202CrossRefGoogle Scholar
  163. Curtis B, Kemp P, Harty L, Choi C, Christensen D (2003) Postmortem identification and quantitation of 2,5-dimethoxy-4-n-propylthiophenethylamine using GC-MSD and GC-NPD. J Analyt Toxicol 27:493–498CrossRefGoogle Scholar
  164. DalCason TA (1989) The characterization of some 3,4-methylendioxyphenylisopropylamine (MDA) analogs. J Forensic Sci 34/4:928–961Google Scholar
  165. Daltrup T (1995) Bestimmung von Cannabinoiden. Toxichem u Krimtech 62:21–27Google Scholar
  166. Daltrup T, Reudenbach G, Kimm K (1987) Cannabis und Alkohol im Straßenverkehr. Blutalkohol 24:144–155Google Scholar
  167. Daltrup T, Käferstein H, Köhler H et al (2000) Entscheidung zwischen einmaligem/gelegentlichem und regelmäßigem Cannabiskonsum. Blutalkohol 37:39–47Google Scholar
  168. Dalterio S, Bartke A (1979) Perinatal exposure to cannabinoids alters male reproductive function in mice. Science 205:1420–1422CrossRefGoogle Scholar
  169. Dargan PI, Hudson S, Ramsey J, Wood DM (2011) The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in “Spice”. Intern H of Drug Policy 22(4):274–277CrossRefGoogle Scholar
  170. Darley CF, Tinklenberg JR, Hollister TE et al (1973) Marihuana and retrieval from short term memory. Psychopharmacol (Berlin) 29:231–238CrossRefGoogle Scholar
  171. Daumann J, Pelz S, Becker S, Tuchtenhagen F, Gouzoulis-Mayfrank E (2001) Psychological profile of abstinent recreational ecstasy (MDMA) users and significance of concomitant cannabis use. Human Psychopharmacol Clin Experimental 16:627–633CrossRefGoogle Scholar
  172. Daunderer M (1979) Therapie einer Atropa-belladonna-Vergiftung mit dem Antidot Physostigmin. Med Welt 30:1743Google Scholar
  173. Davenport J (1966) Aphrodisiacs and love stimulants. Lyle Stuart, New YorkGoogle Scholar
  174. De la Torre R, Farré M, Ortuño J, Mas M, Brenneisen R et al. (2000) Non-linear pharmacokinetics of MDMA (ecstasy) in humans. J Clin Pharmacol 49:104–109CrossRefGoogle Scholar
  175. Delgado PL, Moreno FA (1998) Hallucinogens, serotonin and obsessive-compulsive disorder. J Psychoaktive Drugs 30(4):359–366CrossRefGoogle Scholar
  176. De Luca MA, Castelli MP, Loi B, Porcu A, Martorelli M et al. (2016) Native CB1 receptor affinity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. Neuropharmacol 105:530–638CrossRefGoogle Scholar
  177. Demisch L, Kaczmarczyk P, Seiler N (1978) 3,4,5-Trimethoxybenzoic acid. A new mescaline metabolite in humans. Drug Met Disp 6:507–509Google Scholar
  178. Derungs A, Steuer AE, Mansella G, Bingisser R, Krämer T, Liechti ME (2013) Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201. Forensic Toxicol 31/1:164–171CrossRefGoogle Scholar
  179. Devane WA et al (1992) Isolation and Structure of a Brain Constituent that Binds to the Cannabinoid Receptor. Science 258:1946–1947CrossRefGoogle Scholar
  180. Diaz JL (1979) Ethnopharmacology and Taxonomy of Mexican psychodysleptic plants. J Psychedelic Drugs 11(1–2):71–101CrossRefGoogle Scholar
  181. Dieckhöfer K, Goenchea S (1972) Zur Toxizität von Cannabis. 1 Mitteilung. Med Welt 23:779–782Google Scholar
  182. Diehm J, Pütz M (2009) „Spice“ und vergleichbare Produkte. Harmlose Kräutermischung oder raffinierte Strategie für neue gefährliche Produkte auf dem Rauschgiftmarkt? Kriminalistik 3:131–137Google Scholar
  183. Dietz L, Glaz-Sandberg A, Nguyen H, Mikus G, Aderjan R (2007) Zur Kinetik des 11-Nor-9-carboxy-delta-9-tetrahydrocannabinol-glucuronids im Serum und Urin im Menschen. BA 49:50Google Scholar
  184. Dittrich A, Hofmann A, Leuner M (Hrsg.) (1994) Welten des Bewußtseins. Wissenschaft und Bildung, BerlinGoogle Scholar
  185. Domino EF(1981) Cannabinoids and the cholinergic system. J Clin Pharmacol Suppl 21:149S–255SGoogle Scholar
  186. Domino L, Domino S, Domino EF (1984) Relation of plasma delta-9-tetrahydrocannabinol concentrations to subjective „high“ marijuana users: a review and reanalysis. Academic press, New YorkGoogle Scholar
  187. Don Castro III (1970) Marihuana and the assassins. Br J Addict 65: 35–39CrossRefGoogle Scholar
  188. Doorenbos NJ et al (1971) Cultivation, extraction and analysis of cannabis. Ann NY Acad Sci 191:90–95CrossRefGoogle Scholar
  189. Dornbusch RL, Abrams R, Fink M (1971) Marijuana, memory and perception. Am J Psychiatry 128:194–197CrossRefGoogle Scholar
  190. Dowling GP, McDonough ET, Bost RO (1987) „Eve“ and „Ectasy“. A report of five deaths associated with the use of MDEA and MDMA. JAMA 257/12;1615–1617CrossRefGoogle Scholar
  191. Downer EJ, Fogarty MP, Campbell VA (2001) Delta-9-tetrahydrocannabinol induces the apoptic pathway in cultured cortical neurones via activation of the CB1 receptors. Neuroreport 12(18):2973–3978CrossRefGoogle Scholar
  192. Downer EJ, Fogarty MP, Campbell VA (2003) Tetrahydrocannabinol-induced neurotoxicity depend on CB1-receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons. Br J Pharmacol 140:547–557CrossRefGoogle Scholar
  193. Downing J (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18(4):335–340CrossRefGoogle Scholar
  194. Drasch G, Meyer L von, Roider G, Jägerhuber A (2003) Absolute Fahruntüchtigkeit unter der Wirkung von Cannabis. Vorschlag für einen Grenzwert. Blutalkohol 40:269–286Google Scholar
  195. Drasch G, Meyer L von, Roider G, Staack RF, Pauk LD, Eisenmenger W (2006) Unfälle und reale Gefährdung des Straßenverkehrs unter Cannabis-Wirkung. Blutalkohol 43:441–450Google Scholar
  196. Dziadulewicz EK et al (2007) Naphthalen-1-yl-(4-pentoxynaphthalen-1-yl)methadone: a potent, orally bioavailable human CB1/CB2 dual agoinst with antihyperalgesic properties and restricted central nervous system prnrtration. J Med Chem 50:3851–3856CrossRefGoogle Scholar
  197. Eastman JW, Cohen SN (1975) Hypertensive Crisis and Death Associated with Phencyclidine Poisoning. JAMA 231/12;1270–1271CrossRefGoogle Scholar
  198. Edery H, Soroko D, Kunberg W (1971) Structural requirements for cannabinoid activity. Ann NY Acad Sci 191:139–145CrossRefGoogle Scholar
  199. Efron DH (1970) Psychotomimetic drugs. Raven. New YorkGoogle Scholar
  200. Efron D, Holmstedt B, Kline NS (eds) (1967) Ethnopharmacological search for psychoactive drugs. Public Health Serv Publ 1645:211–216Google Scholar
  201. Ehrenreich H, Rinn T, Kunert H, Moeller MR, Poser W et al (1999) Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacol 142:295–301CrossRefGoogle Scholar
  202. Einhorn LH, Nagy C, Furnas B, Williams SD (1981) Nabilone, an effective antiemetic in patients reveiving cancer chemotherapie. J Clin Pharmacol 9:1314–1319Google Scholar
  203. Einosuke T, Tooru K, Munehiro K, Hitoshi T, Katsuya H (2006) A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy. Feron Sci Entern 163:152–154Google Scholar
  204. Eisner B (1994) Ecstasy: The MDMA-Story. Ronin Publishing, Berkeley, CAGoogle Scholar
  205. Eliade M (1956) Schamanismus und archaische Ekstasetechnik. Rascher, Zürich StuttgartGoogle Scholar
  206. Elian AA (2000) A novel method for GHB detection in urine and its application in drug-facilicated sexual assault. Forensic Sci Int 109:183–187CrossRefGoogle Scholar
  207. Elian AA (2001) GC-MS determination of gamma-hydroxybutyric acid (GHB) in blood. Forensic Sci Int 122:43–47CrossRefGoogle Scholar
  208. Elliot S (2011) Current awareness of piperzines: pharmacology and toxicology. Drug Testing and Analysis 3:430–438CrossRefGoogle Scholar
  209. Elliott S, Smith C (2008) Investigation of the first deaths in the UK involving the detection and quantitation of the piperzanies BZP and 3-TFMPP. J Analyt Toxicol 32(2):172–177CrossRefGoogle Scholar
  210. Elliot SP (2003) Gamma hydroxynutyric acid (GHB) concentrations in humans and factors affecting endogeneous production. Forensic Sci Int 133:9–16CrossRefGoogle Scholar
  211. Elliott SP, Smith C (2008) Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J Analyt Toxicol 32(2):172–177CrossRefGoogle Scholar
  212. Ellis GM Jr et al (1985) Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Therap 38:572–578CrossRefGoogle Scholar
  213. EMCDDA (2009) Report on the risk assessment of BZP in the framework of the Council Decision on new psychoactive substances. European Monitoring Center for Drugs and Drug AddictionGoogle Scholar
  214. EMCDDA (2009) Unterstanding the „Spice“ phenomenon. Thametic papers. European Monitoring Center for Drugs and Drug AddictionGoogle Scholar
  215. EMCDDA (2011) Drug profile: Synthetic cannabinoids and „Sice“. European Monitoring Center for Drugs and Drug AddictionGoogle Scholar
  216. EMCDDA (2011) BZP and other piperazines. European Monitoring Center for Drugs and Drug AddictionGoogle Scholar
  217. Enßlin HK et al (1990) Trennung von MDA, MDE, MDMA: Verbindung von AMD-Technik und DC/IR-Koppelung. Toxichem/Krimtech 6(57):164–168Google Scholar
  218. Ernst L, Schiebel H-M, Theuring C, Lindigkeit R, Beuerle T (2011) Identification and characterization of JWH-122 used as new ingredient in „Spice-like“ herbal incenses. Forensic Sci Int 208:e31–e35CrossRefGoogle Scholar
  219. Estrada A (1980) Maria Sabina. Botin der heiligen Pilze. Trikont, MünchenGoogle Scholar
  220. Eugster CH (1968) Wirkstoffe aus dem Fliegenpilz. Naturwissenschaften 55:305–313CrossRefGoogle Scholar
  221. Every-Palmer S (2011) Syntheic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 117(2–3):152–157CrossRefGoogle Scholar
  222. Ewald AH, Jacobsen-Bauer A, Klein B, Uhl M (2013) Gemeinsamer Vorschlag des Arbeitskreises Analytik der Suchstoffe der CTFCh zur besseren analytischen Bewältigung der großen Anzahl und Vielfalt von “Kräutermischungen“ NStZ 5:265–267Google Scholar
  223. Fabre LF, McLendon D (1981) The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol 21:377–382CrossRefGoogle Scholar
  224. Fallon JK, Kicman AT, Henry JA, Milligan PJ et al. (1999) Stereospecific analysis and enantiomeric disposition of methylenedioxymethamphetamine (Ecstasy) in humans. Clin Chem 45:1058–1069Google Scholar
  225. Farfel GM et al (1995) Role of hypothermia in the mechanism of protection against serotonergic toxicity. J Pharmacol Exp Ther 272(2,1):860–867, 11;868–875Google Scholar
  226. Farnsworth NR (1968) Halluzinogenic plants. Science 162:96–105CrossRefGoogle Scholar
  227. Feldman HW et al (eds) (1979) Angel dust: An ethnographic study of PCP users. Lexington Books, Lexington/MAGoogle Scholar
  228. Ferdi (Pseudonym) (1996) zu hause züchten. leitfaden für einsteiger. 3. Aufl. Grassberry Productions, HeerlenGoogle Scholar
  229. Fergusson DM, Horwood LJ, Swain-Campbell N (2002) Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addict 97:1123–1135CrossRefGoogle Scholar
  230. Feucht A, Bagli M, Stephan R et al. (2004) Pharmacokinetics of m-Chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmakodynamic profile. Pharmacopsychiatry 37:180–188CrossRefGoogle Scholar
  231. Feuerlein W (Hrsg.) (1980) Cannabis heute. Bestandsaufnahme zum Haschischproblem. Akademische Verlagsgesellschaft, WiesbadenGoogle Scholar
  232. Fink DJ, Ashworth B, Brewer C (1972) Cerebral atrophy in young cannabis smokers. Lancet 1:143–147CrossRefGoogle Scholar
  233. Fischer C, Hatzidimitrion G, Wios J, Kath J, Recautre G (1995) Reorganization of Ascending 5-HT Axon Projections in Animal Previously Exposed to the Recreational Drug MDMA (,Ecstasy‘). J of Neurosci 8:5476–5485CrossRefGoogle Scholar
  234. Fischer J, Täschner K-L (1991) Flash back nach Cannabis-Konsum – eine Übersicht. Fortschr Neurol Psychiatr 59:437–446CrossRefGoogle Scholar
  235. Fisher G, Steckler A (1974) Psychological effects, personality and behavioral changes attributed to marihuana use. Int J Addict 9:101–126CrossRefGoogle Scholar
  236. Fligiel SEG, Venkat H, Gong H, Tashkin DP (1988) Bronchial pathology in chronic marijuana smokers: a light and electron microscopic study. J Psychoactive Drugs 20:33–42CrossRefGoogle Scholar
  237. Flom MC, Adams AJ, Jones RT (1975) Marijuana smoking and reduced pressure in human eyes: drug action or epiphenomenon? Invest Ophthalm 14:52–55Google Scholar
  238. Forstenhäusler D (1993) Synthetische Drogen. Kriminalistik 8–9: 533–558Google Scholar
  239. Frank M, Rosenthal E (1974) Marijuana Grower’s Guide. And/Or Press, San FranciscoGoogle Scholar
  240. Franks HM, Starmer GA, Chesher GB, Jackson DM, Hensley VR, Hensley WJ (1975) The interaction of alcohol and delta-9-tetrahydrocannabinol in man. Effects on psychomotor skills related to driving. Add Res Fond of Ontario, TorontoGoogle Scholar
  241. Frederick DL et al (1985) Comparison of six cannabinoid metabolite assays. J Anal Tox 9:116–120CrossRefGoogle Scholar
  242. Frederking W (1955) LSD-25 and mescaline in psychotherapy. J Ment Dis 121:70–77Google Scholar
  243. Freedman DX (1963) Psychotomimetic drugs and brain biogenic amines. Am J Psychiatry 119:843– 850CrossRefGoogle Scholar
  244. Fride E, Shohami E (2002) The endocannabinoid system: function in survival of the embryo, the newborn and the neuron. Neuroreport 13(15):1833–1841CrossRefGoogle Scholar
  245. Fried PA (1977) Behavioral and electroencephalographic correlates of the chronic use of marihuana – a review. Bull Narc 29(2):29–34Google Scholar
  246. Fried P, Watkinson B, James D, Gray R (2003) Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults. Can Med Ass J 66(7):887–891Google Scholar
  247. Friedberg C (1965) Des Banisteriopsis utilisés comme drogue en Ameriqué du sud. J Agric Trop Bot Appl 12:403–437, 550–594, 729–780Google Scholar
  248. Furst PT (1971)Ariocarpus retusus, the „false peyote“ of Huichol tradition. Econ Bot 25(1):182–187CrossRefGoogle Scholar
  249. Furst PT (ed) (1972) Flesh of the gods: The ritual use of hallucinogens. Prager, New YorkGoogle Scholar
  250. Furst PT (1976) Hallucinogens and culture. Chandler & Sharp, San FranciscoGoogle Scholar
  251. Galanter M, Wyatt R, Lemberger L et al (1972) Marijuana intocication: Interaction between physiologic effects and subjektive experience. Sci 176:934–936CrossRefGoogle Scholar
  252. Gale EN, Guenther G (1971) Motivational factors associated with the use of Cannabis. Br J Addict 13:30–36Google Scholar
  253. Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Sci 86:136–147Google Scholar
  254. Garrett ER, Hunt CA (1977) Separation and analysis of Δ1-tetrahydrocannabinol in biological fluids by high-pressure liquid chromatopgraphy and GLC. J Pharm Sci 66:20–26CrossRefGoogle Scholar
  255. Gartz J (2001) Salvia divinorum – Der Wahrsagesalbei. Nachtschatten VerlagGoogle Scholar
  256. Gautier T (1846) Le club des hachichins. Revue des Deux MondesGoogle Scholar
  257. Gee P, Jerram T, Bowie D (2010) Multiorgan failure from 1-benzylpiperazine ingestion – legal high or letal high? Clin Toxicol (Philadelphia) 48(3):230–233CrossRefGoogle Scholar
  258. Gerhard H (2001) Party-Drugs: Sociocultural and individual background and risks. Int J Clin Pharmacol and Therapeutics 39(8):362–366CrossRefGoogle Scholar
  259. Gerlach D, Schüling S (1984) Phencyclidin, Hinweise zur Erkennung und Behandlung von PCP-Intoxikationen. Suchtgefahren 30:273–279Google Scholar
  260. Ghaziuddin N, Welch K, Greden J (2003) Central Seretonergic Effects of m-Chlorophenylpiperazine (mCPP) among Normal Control Adolescents. Neuropsychopharmacol 28:133–139CrossRefGoogle Scholar
  261. Gielsdorf W, Klug E (1981) Neues Rauschmittel auf dem Drogenmarkt: 2,5-Dimethoxy-4bromamphetamin (DOB). Dtsch ApothZ 20:1003–1005Google Scholar
  262. Gilmour DG, Bloom AD, Kusum PL, Robbins ES, Maximilian C (1971) Chromosomal aberrations in users of psychoactive drugs. Arch Gen Psychiatry 24:268–272CrossRefGoogle Scholar
  263. Glennon RA, Ismaiel AEM, Martin B, Poff D, Sutton M (1988) A preliminary behavioral investigation of PMMA the 4-methoxy analog of methamphetamine. Pharmacol Biochem and Behavior 31(1):9–13CrossRefGoogle Scholar
  264. Gobbi M, Moia M, Pirona L et al. (2002) p-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatews in their mode of action at 5-HT nerve endings in vivo. J Neurochem 82:1435–1443CrossRefGoogle Scholar
  265. Goenchea S, Dieckhöfer K (1972) Zur Toxizität von Cannabis. 2. Mitteilung. Med Welt 23:1148–1151Google Scholar
  266. González D, Riba J, Bouso JC et al (2006) Pattern of use and subjektive effects of Salvia divinorum among recreational users. Drug Alcohol Depend 85:157–162CrossRefGoogle Scholar
  267. Goodall CR, Basteyns BJ (1995) A reliable method for the detection, confirmation, and quantitation of cannabinoids in blood. J Anal Toxicol 19:419–426CrossRefGoogle Scholar
  268. Goode E (1970) The marijuana smokers. Basic, New YorkGoogle Scholar
  269. Gorman M, Neuss N, Cone NJ (1965) Vinca alkaloids, XVII. Chemistry of catharanthine. J Am Chem Soc 87:93–98CrossRefGoogle Scholar
  270. Gostomzyk JG, Gewecke M, Eisele G (1971) Vergleichende Untersuchungen zur Verkehrstauglichkeit nach Haschischkonsum und nach einer Kurznarkose. Med Welt 22:1785Google Scholar
  271. Gostomzyk JG, Parade P, Gewecke H (1973) Rauschmittelgenuss und Leistungsfähigkeit (Untersuchungen zur Energiebildung unter Haschisch). Z Rechtsmed 73:131–136CrossRefGoogle Scholar
  272. Gouzoulis-Mayfrank E, Hermle L, Kovar KA, Sass H (1996) Die Entaktogene Ecstasy (MDMA), Eve (MDE) und andere ringsubstituierte Methamphetaminderivate. Nervenarzt 67:369–380Google Scholar
  273. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA et al (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methylen-dioxyethylamphetamine (MDE), psilocybin und d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacol (Berlin) 142(1):41–50CrossRefGoogle Scholar
  274. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S et al (2000) Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurology Neurosurgery Psychiatry 68:719–725CrossRefGoogle Scholar
  275. Gouzoulis-Mayfrank E, Becker S, Pelz S, Tuchtenhagen F, Daumann J (2002) Neuro-endocrine abnormalities in recreational ecstasy (MDMA) users: is it ecstasy or cannabis. Biol Psychiatry 51(9):766–769CrossRefGoogle Scholar
  276. Granier M (1962) Native halluzinogene Arzneimittel aus Piptadenia. Bull Narcotics 17:29Google Scholar
  277. Grant BF, Pickering R (1999) The relationship between cannabis use and DSM-IV cannabis abuse and dependence: Results from the National Longitudinal Alcohol Epidemiology Survey. J Subst Abuse Treat 10:255–264CrossRefGoogle Scholar
  278. Graw M, Mußhoff F (2016) THC als Arzneimittel – Frage nach Fahrsicherheit und der Fahreignung, Blutalkohol 53:289–297Google Scholar
  279. Green AR, Mechan AO, Elliot JM, O’Shea E, Colado I (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”). Pharmacol Rev 55:463–508CrossRefGoogle Scholar
  280. Green KS (1984) Discussion of the use of marihuana, ethanol, and other drugs among drivers killed in single vehicle crashes. J Forensic Sci 29:16–21Google Scholar
  281. Green K (1975) Marihuana and the eye. Invest Ophthalm 14:261–263Google Scholar
  282. Grella CE, Hser YI, Joshi V, Rouds-Bryant J (2001) Drug treatment outcomes for adolescents with co-morbid mantal and substance use disorders. J Nerv Ment Dis 189:384–392CrossRefGoogle Scholar
  283. Grenn K, Podos SM (1974) Antagonism of arachidonic acid induced ocular effects by delta-tetrahydrocannabinol. Invest Ophthalm 13: 422–429Google Scholar
  284. Green AR, Gross AJ, Goodwin GM (1995) Review of the pharmacology of MDMA. Psychopharmacol 119:247–260CrossRefGoogle Scholar
  285. Green AR, Goodwin GM (1996) Ecstasy and neurodegeneration. Brain Med J 312:1493CrossRefGoogle Scholar
  286. Green K, Kim K (1976) Interaction of adrenergic antagonists with prostaglandin E2 and tetrahydrocannabinol in the eye. Invest Ophthalm 15:102–112Google Scholar
  287. Grenzwertkommission (2011) Naturwissenschaftliche Grundlagen der Fahrlässigkeit – Zeitspanne der Nachweisbarkeit – Zuverlässigkeit von Drogenvortests. Blutalkohol 48:72–79Google Scholar
  288. Grinker RR (1964) Bootlegged ecstasy. JAMA 187:768CrossRefGoogle Scholar
  289. Grinspoon L, Bakalar JB (1981) Psychedelic drugs reconsidered. Basic, New YorkGoogle Scholar
  290. Grob CS, Poland RE, Chang L, Ernst T (1996) Psychobiologic effects of 3,4methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 73(1–2):103–107Google Scholar
  291. Grof S (1983) LSD-Psychotherapie. Klett-Cotta, StuttgartGoogle Scholar
  292. Gröger D (1966) Fortschritte der Chemie und Biochemie der Mutterkornalkaloide. Fortschr Chem Forsch 6:159–164CrossRefGoogle Scholar
  293. Gross D (1971) Vorkommen, Struktur und Biosynthese natürlicher Piperidinverbindungen. Fortschr Chem Org Naturstoffe 29:1–8Google Scholar
  294. Grotenthermen F (1999) Some practice-relevant aspects of the pharmacokinetics of THC. Forsch Komplementarmed 6 Suppl 3:37–39Google Scholar
  295. Grotenthermen F (Hrsg.) (2004) Cannabis und Cannabinoide. Pharmakologie, Toxikologie und therapeutisches Potential. Hans Huber, Bern/Göttingen/Toronto/SeattleGoogle Scholar
  296. Grotenthermen F (2006) Cannabinoide und das Endocannabinoidsystem, Cannabinoids 1:11–16Google Scholar
  297. Grotenthermen F, Huppertz R (1997) Hanf als Medizin. Hang/Hüthig, HeidelbergGoogle Scholar
  298. Gruenwaldt G (1971) Haschisch, Marihuana, LSD – Eigenschaften, Bedeutung, Gefahren. Saarl Ärztebl 24:33–37Google Scholar
  299. Grundmann O, Phipps SM, Zadezensky I et al (2007) Salvia divinorum and salvinorin A: An update on pharmacology and analytical methodology. Planta Medica 73:1039–1046CrossRefGoogle Scholar
  300. Grupp SE (1972) Multiple drug use in a sample of experienced smokers. Int J Addict 7:481–491CrossRefGoogle Scholar
  301. Gudelsky GA, Yamamoto BK, Nash JF (1994) Potentiation of 3,4-methylendioxymethamphetamine-induced dopamine release and sorotonin neurotoxicity by 5-HT2 agonists. Eur J Pharmacol 264:325–330CrossRefGoogle Scholar
  302. Hess C, Maas A, Madea B (2014) „Legal highs“ – Chemie, Pharmakologie, Toxikologie und forensische Bedeutung. Rechtsmedizin 24:291–305CrossRefGoogle Scholar
  303. Haan J, Binder M (1980) Psychotrope Drogen: Halluzinogene und Psychostimulantien. Intern Welt 5:153–160Google Scholar
  304. Habschick K (2014) Cannabis: „Legalize it“ – not! Kriminalistik 11:627–635.Google Scholar
  305. Habschick K (2014) Cannabis: „Legalize it“ – not! Teil 2. Kriminalistik 12:705–711Google Scholar
  306. Haenel TA (1970) Kulturgeschichte und heutige Problematik des Haschischs. Pharmakopsychiat Neuropsychopharmakol 3:89–115CrossRefGoogle Scholar
  307. Hänsel W (1979) Struktur und Wirkung von Halluzinogenen. Chem in unserer Zeit 13:147CrossRefGoogle Scholar
  308. Hai H (1984) Das Hanfhandbuch. Piper, Löhrbach (Der grüne Zweig, Bd. 73)Google Scholar
  309. Haines JD (1998) Absinthe – Return of the green fairy. J Oklahoma State Med Assoc 91:406–407Google Scholar
  310. Halikas JA, Goodwin DW, Guze SB (1972) Marihuana use and psychiatric illness. Arch Gen Psychiatry 27:162–165CrossRefGoogle Scholar
  311. Hall W, Solowij N (1998) Adverse effects of cannabis. Lancet 352:1611–1616CrossRefGoogle Scholar
  312. Hall W, Degenhardt L (2009) Adverse health effects of non-medical cannabis use. Lancet 374:1383–1391CrossRefGoogle Scholar
  313. Hall W, Degenhardt L (2014) The adverse health effects of chronic cannabis use. Drug Test Anal 6:39–45CrossRefGoogle Scholar
  314. Hallucinogenic and Psychedelic Drug Synthesis. Manual (1976) Salt and Pepper Syndicate. Lawrence/KSGoogle Scholar
  315. Hammer T, Vaglun P (1990) Initiation, continuation or discontinuation of cannabis use in the general population. Br J Addict 85:899–909CrossRefGoogle Scholar
  316. Hansjakob T (1999) Hanfshops – Gesundheitszentren oder Drogenumschlagplätze? Kriminalistik 4:273–277Google Scholar
  317. Harding R, Knight F (1973) Marihuana-modified mania. Arch Gen Psychiatry 29:635–637CrossRefGoogle Scholar
  318. Harding WW, Tidgewell K, Byrd N et al (2005) Neoclerodane diterpenes as a novel scaffold for μ opioid receptor ligands. J Med Chem 48:4765–4771CrossRefGoogle Scholar
  319. Harner MJ (ed) (1973) Hallucinogens and shamanism. Oxford Univ Press, LondonGoogle Scholar
  320. Harvey DJ (1985) Marihuana 1984. IRL Press, OxfordGoogle Scholar
  321. Harzer K (1982) Nachweis von LSD in Körperflüssigkeiten mit Hochdruckflüssigkeitschromatographie. J Chromatogr 249:205–211CrossRefGoogle Scholar
  322. Hashimoto K et al (1992) Effects of benzylpiperazine derivatives on the neurotoxicity of MDMA in rat brain. Brain Res 590(1–2): 341–344CrossRefGoogle Scholar
  323. Hasse HE,Waldmann H (1971) „Flashback“: Spontane psychotische Episoden als Folgeerscheinung des Phantasticagebrauchs Jugendlicher. Arch Psychiatr Nervenkr 214:399–439CrossRefGoogle Scholar
  324. Hawkes JG et al (eds) (1979) The biology and taxonomy of the solanaceae. Academic Press, LondonGoogle Scholar
  325. Hawks RL (1982) The constituentes of cannabis and the disposition and metabolism of cannabinoids. Nat Int Drug Abuse Res Monogr Ser 42:125–137Google Scholar
  326. Heath RG (1976) Marihuana and delta 9 tetrahydrocannabinol: Acute and chronic effects an brain function of monkeys. In: Braude MC, Szara S (eds) Pharmacology of marihuana. Raven, New York, pp 345–356Google Scholar
  327. Heath RG, Fitzjarrell AT, Garey RE, Myers WA (1979) Chronic marihuana smoking: Its effets on function and structure of the primate brain. In: Nahas GG, Paton WDM (eds) Marihuana: Biological effects. Pergamon, New York, pp 713–730CrossRefGoogle Scholar
  328. Hecker RM, Röhrich J, Neis P, Rittner C (2003) Phänomenologie der Akutwirkungen von „Partydrogen“ bei Diskothekenbesuchern. Blutalkohol 40:85–103Google Scholar
  329. Heim ME (1982) Cannabis und Cannabinoide. Fortschr Med 9:343–346Google Scholar
  330. Heim R (1967) Nouvelles investigations sur les champignons hallucinogènes. Editions des Musées Nationaux Histoire, ParisGoogle Scholar
  331. Heim R, Wasson RG (1958) Les champignons hallucinogènes du Mexique. Editions des Musées Nationaux Histoire, ParisGoogle Scholar
  332. Heimann H (1961) Ausdrucksphänomenologie der Modellpsychosen (Psilocybin). Psychiat Neurol 141:69–100CrossRefGoogle Scholar
  333. Hein J, Lobbedey L, Neumärker KJ (2001) Absinth – Neue Mode, alte Probleme. Dtsch Ärztebl 98:2166–2171Google Scholar
  334. Heinemann C (1971) Klinisch beobachtete Folgeerscheinungen nach Haschischkonsum. Med Klin (Munich) 66:1648–1653Google Scholar
  335. Heinemann C (1973) Nachlassende Wirkung initialer Rauscherlebnisse und Dosissteigerung beim Haschischkonsumenten. Med Klin 68: 826–830Google Scholar
  336. Heinke DH (2004) Fahruntüchtigkeit aufgrund drogeninduzierter Einschränkung der Sehfähigkeit. Blutalkohol 41:241–246Google Scholar
  337. Heishman Sj, Singleton EG, Liguori A (2001) Marijuana craving questionnaire: development and initial validation of a self-report instrument. Addict 96:1023–1034CrossRefGoogle Scholar
  338. Helmer R, Wunder R, Zellmann K, Haesen D (1972) Experimentelle Untersuchungen zur Fahrtüchtigkeit nach Einnahme von Haschisch. Blutalkohol 4:213–220Google Scholar
  339. Henderson GL (1988) Designer drugs, past history and future prospects. J Forensic Sci 33(2):569– 575CrossRefGoogle Scholar
  340. Henderson RL, Tennant FS, Guerry R (1972) Respiratory manifestations of hashish smoking. Arch Otolarnygol 95:248–251CrossRefGoogle Scholar
  341. Henry JA (1999) Ecstasy and the dance of death. Brit Med J 305(7): 5–6Google Scholar
  342. Hepler RS, Frank IM (1971) Marihuana smoking and intraocular Pressure. JAMA 217:1392CrossRefGoogle Scholar
  343. Herer J (1993) Die Wiederentdeckung der Nutzpflanze Hanf-Cannabis-Marihuana. 2000, Frankfurt am MainGoogle Scholar
  344. Herha J (1974) Haschisch und Marihuana – eine Übersicht. Naturwissenschaften 61:90–94CrossRefGoogle Scholar
  345. Hernández-López C, Farré M, Roset PN, Menoyo E et al. (2002) 3,4-Methylenedioxymethamphetamine (Ecstasy) and alcohol interactions in hums. Psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 300:236–244CrossRefGoogle Scholar
  346. Herning RI, Jones RT, Peltzmann DJ (1979) Changes in human event relate potentials with prolonged delta-9-tetrahydrocannabinol (THC) use. Electroencephalogr Clin Neurophysiol 47:556–570CrossRefGoogle Scholar
  347. Hermann TS, Einhorn LH, Jones SE, Nagy C, Chester AB et al (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Eng J Med 300(23):1295–1297CrossRefGoogle Scholar
  348. Hess C, Schroeder CT, Müller CE, Madea B (2013) CB1 and CB2 receptor affinities of synthetic cannabinoids sold on the illicit drug market. Toxichem Krimtech 82(2):111Google Scholar
  349. Hess C, Schroeder CT, Pillaiyar T, Madea B, Müller CE (2016) Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice. Forensic Toxicol 34(2):329–343CrossRefGoogle Scholar
  350. Hesse M (1964/1968) Indolalkaloide in Tabellen. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  351. Hesse M (1974) Progress in mass spectrometry, vol 1: Indolalkaloide. Verlag Chemie, WeinheimGoogle Scholar
  352. Hill SL, Thomas SH (2011) Clinical toxicology of newer recreational drugs. Clin Toxicol 49(8):705–719CrossRefGoogle Scholar
  353. Hingson R, Alpert JS, Day N et al (1982) Effects of maternal drinking and marihuana use on fetal growth and development. Pediatrics 70:539–546Google Scholar
  354. Hirschhorn K, Cohen MM (1968) Drug-induced chromosomal aberrations. Ann NY Acad Sci 151:977–987CrossRefGoogle Scholar
  355. Hoch E, Bonnet U, Thomasius R, Ganzer F, Havemann-Reinecke U, Preuss U (2015) Risiken bei nichtmedizinischem Gebrauch von Cannabis. Dt Ärztebl 16:271–278Google Scholar
  356. Hochman JS, Brill NQ (1973) Chronic marijuana use and psychosocial adaption. Am J Psychiatr 130:132–139CrossRefGoogle Scholar
  357. Hoffer A, Osmond H (1967) The hallucinogens. Academic Press, New YorkGoogle Scholar
  358. Hoffmann D, Brunnemann KD, Gori GB, Wynder EL (1975) On the carcinogenicity of marijuana smoke. Res Adv Phytochem 9:63–81CrossRefGoogle Scholar
  359. Hofmann A (1954) Die Isolierung weiterer Alkaloide aus Rauwolfia serpentina Benth. Helv Chim Acta 37:849–865CrossRefGoogle Scholar
  360. Hofmann A et al (1958) Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen Rauschpilz Psilocybe mexicana Heim. Experimentia XIV 3:107–112CrossRefGoogle Scholar
  361. Hofmann A (1960a) Psychotomimetica, eine Übersicht. Svensk Kem Tidskr 72:79–88Google Scholar
  362. Hofmann A (1960b) Die psychotropen Wirkstoffe der mexikanischen Zauberpilze. Chimia 14:309– 318Google Scholar
  363. Hofmann A (1960c) Isolierung von Lysergsäurealkaloiden aus der mexikanischen Zauberdroge Ololiuqui. Experimentia 16:414–420CrossRefGoogle Scholar
  364. Hofmann A (1961) Die Wirkstoffe der mexikanischen Zauberdroge Ololiuqui. Planta Med 9:354– 367CrossRefGoogle Scholar
  365. Hofmann A (1964) Die Mutterkornalkaloide. Enke, StuttgartGoogle Scholar
  366. Hofmann A (1967) Psychoaktive Stoffe der Pflanzen. Therapiewoche 35: 40–47Google Scholar
  367. Hofmann A (1979) LSD – mein Sorgenkind. Klett-Cotta. Stuttgart.Google Scholar
  368. Hofmann A (1981) LSDisteinesakraleDroge(InterviewmitDr. Hofmann). PsycholHeute 4:55–61Google Scholar
  369. Hofmannn A, Tscherter H (1960) Isolierung von Lysergsäurealkaloiden aus der mexikanischen Zauberdroge Ololiuqui. Experimantia XVI/9Google Scholar
  370. Hohmann N, Mikus G, Czock D (2014) Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals. Dtsch Ärztebl Int 111(9):139–147Google Scholar
  371. Hokkanen E, Waltimo O, Kallauranta J (1978) Toxic effects of ergotamine used for migraine. Headache 18:95–98CrossRefGoogle Scholar
  372. Höld KM, Sirisoma NS, Ikeda T, Narahashi T, Casida JE (2000) a-Thujone (the active component of absinthe): g-Aminobutyric acid type A receptor modulation and metabolic detoxification. Proc Natl Acad Sci USA 97:3826–3831CrossRefGoogle Scholar
  373. Hole G (1967) LSD und verwandte Halluzinogene. Geschichte –Wirkung – Gebrauch und Gefahren. MMW 109:1389–1397Google Scholar
  374. Hollister LE (1968) Chemical psychoses. LSD and related drugs. Thomas, Springfield/ILGoogle Scholar
  375. Hollister LE (1986) Health Aspects of Cannabis. Pharmacol Rev 38:1–20Google Scholar
  376. Hollister LE, Gillespie HK, Ohlsson A (1981) Do plasma concentrations of Δ9-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharm 21:171s–177sCrossRefGoogle Scholar
  377. Hollister LE, Richards RK, Gillspie HK (1986) Comparison of Δ9-tetrahydrocannabinol and synhexyl in man. Clin Pharmacol Ther 9: 783–791CrossRefGoogle Scholar
  378. Honecker HC, Coper C (1970) Dünnschichtchromatographische Nachweismethode von Opium als Beimengung in Haschisch-Proben. Dtsch Med Wochenschr 42:441–443Google Scholar
  379. Horowitz MJ (1969) Flashbacks: recurrent intrusive images after the use of LSD. Am J Psychiatry 126:147–151CrossRefGoogle Scholar
  380. Howlett AC et al (2002) Classification of cannabinoid receptors. Intern Union of Phrmacol XXVII, 54(2):161–202Google Scholar
  381. Hudson S, Ramsey J (2011) The emergence and analysis of synthetic cannabinoids. Drug Testing and Analysis 3:466–478CrossRefGoogle Scholar
  382. Huestis MA, Henningfield VE, Cane ED (1992) Blood Cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking Marihuana. J Anal Toxikol 16:276–282CrossRefGoogle Scholar
  383. Huestis MA, Cone EJ (2004) Relationship of Delta-9-tetrahydrocannabinol concentrations in oral fluid ans plasma after controlled administration of smoked cannabis. J Anal Toxicol 28:394–399CrossRefGoogle Scholar
  384. Huffman JW, Zengin G, Wu MJ, Lu J et al (2005) Structure-activity relationships for 1-alkyl3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphtoyl substituents. New highly selective CB(2) recptor agonists. Bioorg Med Chem 13:89–112CrossRefGoogle Scholar
  385. Hufmmann JW, Thompson ALS, Wiley JL, Martin BR (2008) Synthesis and Pharmacology of 1-Deoxy Analogs of CP-47,497 and CP-55,940. Bioorg Med Chem 16(19):322–335CrossRefGoogle Scholar
  386. Huffman JW (2009) Cannabimimetic indoles, pyrroles, and indenes: structure-activity relationships and receptor interactions, in: Reggio PH (ed.) The cannabinoid receptors. Humana Press/Springer, New YorkGoogle Scholar
  387. Hunt CA, Jones RT (1980) Tolerance and disposition of tetrahydrocannabinbol in man. J Pharm Exp Ther 215:35–44Google Scholar
  388. Hunt CA, Jones RT, Herning RI, Bachmann J (1981) Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. J Pharmacokinet Biopharm 9:245– 260CrossRefGoogle Scholar
  389. Huxley A (1972) The doors of perception (dtsch Übers: Die Pforten der Wahrnehmung. Piper, München)Google Scholar
  390. Imanshahidi A, Hosseinzadeh H (2006) The pharmacological effects of Salvia species on the central nervous system. Phytotherapy Research 20:427–437CrossRefGoogle Scholar
  391. Isbell H, Gorodetzky CW, Jasinsky D, Claussen U, Spulak F, Korte F (1967) Effects of (-)-delta-9transtetrahydrocannabinol in man. Psychopharmacologia (Berlin) 11:184–188CrossRefGoogle Scholar
  392. Iversen L (2003) Cannabis and the brain. Brain 126:1252–1270CrossRefGoogle Scholar
  393. Iversen L, Gibbons S, Treble R, Setola V, Huang X-P, Roth BL (2013) Neurochemical profiles of some novel psychoactive substances. Eur J Pharmacol 700(1-3):147–151CrossRefGoogle Scholar
  394. Jacobson CB, Berlin CM (1972) Possible reproductive detriment in LSD users. JAMA 222:1367– 1373CrossRefGoogle Scholar
  395. Jakubovic A, McGeer D (1972) Inhibition of rat brain protein by cannabinoids in vitro. Can J Biochem 50:654–660CrossRefGoogle Scholar
  396. Janowsky DS, Meacham MP, Blaine JD, Schoor M, Bozetti LP (1976a) Simulated flying performance after marihuana intoxication. Aviat Space Environ Med 47:124–128Google Scholar
  397. Janowsky DS et al (1976b) Marijuana effects an simulated flying ability. Am J Psychiatry 133:384–388CrossRefGoogle Scholar
  398. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR et al (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia. J Clin Oncology 20(2):567–573CrossRefGoogle Scholar
  399. Johannsson E, Halldin MM, Agurell S, Hollister LE, Gillespie HK (1989) Terminal elimination plasma half-live of D-(1)-tetrahydrocannabinol (D(1)-THC) in heavy users of marijuana. Eur J Clin Pharmacol 37(3):273–277CrossRefGoogle Scholar
  400. Johns A (2001) Psychiatric effects of cannabis. Br J Psychiat 178:116–122CrossRefGoogle Scholar
  401. Johnson MP, Fescas SP, Oberlender R, Nichols DE (1991) Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA). J Medicinal Chem 34(5):1662–1668CrossRefGoogle Scholar
  402. Johnson S, Domino EF (1971) Some cardiovascular effects of marihuana smoking in normal volunteers. Therapeutics 12:762–768Google Scholar
  403. Johnstone RE (1973) A Ketamine trip. Anesthesiol 39:460–461CrossRefGoogle Scholar
  404. Jones AB, ElSohly HN et al (1984) Analysis of the Major Metabolite of Delta-9-tetrahydrocannabinol in Urine. An Comparison of Five Methods. J Anal Toxikol 8:249–251CrossRefGoogle Scholar
  405. Jones H, Jones HC (1977) Sensual drugs. Cambrigde Univ Press, CambridgeGoogle Scholar
  406. Jones HC, Lovinger PW (1985) The marihuana question. Mead, New YorkGoogle Scholar
  407. Jones R (1977) Human effects. NIDA Res Monogr 14:128–178Google Scholar
  408. Joyce CRB, Currv SH (1970) The botany and chemistry of cannabis. Churchill, LondonGoogle Scholar
  409. Kaiser C, Gold R (1974) Perception, psychedelics and social change. J Psychedelic Drugs 6:30–35CrossRefGoogle Scholar
  410. Kandel D, Chen K (2000) Types of marihuana users by longitudinal course. J Stud Alcohol 61:367–378CrossRefGoogle Scholar
  411. Kang S et al (1970) Correlation between activity and electronic state of hallucinogenic amphetamines. Nat 226:645–647CrossRefGoogle Scholar
  412. Kannheiser W (2000) Mögliche verkehrsrelevante Auswirkungen von gewohnheitsmäßigem Cannabiskonsum. NZV 13:57–68Google Scholar
  413. Kanter SL, Hollister LE (1977) Marihuana metabolites in urine of man. Res Commun Chem Pathol Pharmacol 17:421–431Google Scholar
  414. Kaplan HS (1971) Psychosis associated with marijuana. NY State J Med 71:433–435Google Scholar
  415. Karler R (1977) Toxicological and pharmacological effects. NIDA Res Monogr 14:55–66Google Scholar
  416. Karler R, Cely W, Turkanis SA (1974a) Anticonvulsant properties of Δ9-tetrahydrocannabinol and other cannabinoids. Life Sci 15:931–947CrossRefGoogle Scholar
  417. Karler R, Cely W, Turkanis SA (1974b)A study of the development of tolerance to an anticonvulsant effect of delta-9-THC and cannabidiol. Res Commun Chem Pathol Pharmacol 9:23–29Google Scholar
  418. Karschner EL, Schwilke EW, Lowe RH, Darwin WD et al. (2009) Implications of plasma delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol 33:469–477CrossRefGoogle Scholar
  419. Katzung W (1990) Drogen: Informationen in Übersichten IV. Abhängigkeit vom Cannabis-Typ. Leitdroge THC. Medizin aktuell 16: 568–570Google Scholar
  420. Katzung W et al (1991) Psilocybe-Pilze-Drogen vor der Haustür? Medizin aktuell 17:654–655Google Scholar
  421. Katzung W, Harfst G (2001) Synthetische Amphetamin-Drogen. Holger Harfst Verlag, WürzburgGoogle Scholar
  422. Kaymakcalan S (1975) Potential dangers of cannabis. Int J Addict 10:721–735CrossRefGoogle Scholar
  423. Keller K, Stahl E (1982) Kalmus: Inhaltsstoffe und Asarongehalt bei verschiedenen Herkünften. Dtsch Apoth Z 122(48):2463–2466Google Scholar
  424. Kelly P, Jones RT (1992) Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 16:228–235CrossRefGoogle Scholar
  425. Kemali M, Kemali D (1980) Lysergic acid diethylamide: Morphological study of its effects on synapsis. Psychopharmacol 69:315–317CrossRefGoogle Scholar
  426. Kemp PM, Abukhalaf JE, Manno BR et al (1995) Cannabinoids in humans. I. Analysis of delta-9tetrahydrocannabinol and six metabolits in urine using GC-MS. J Anal Toxicol 19:285–291CrossRefGoogle Scholar
  427. Kennedy AB, Rätsch C (1985) Datura: Aphrodisiac? High Frontiers, BerkeleyGoogle Scholar
  428. Keup W (1967) Psychotic symptoms due the cannabis abuse (a survey of newly admitted mental patients). Dis Nerv Syst 31:119–126Google Scholar
  429. Keup W (1990) Analoga kontrollierter Substanzen – Entwicklung des Missbrauchs in der BRD. Suchtgefahren 36:251–259Google Scholar
  430. Kielholz P, Hobi V, Ladewig D, Miest P, Richter R (1973) An experimental investigation about the effect of cannabis on car absorption. Pharmakopsychiatry 6:91–103CrossRefGoogle Scholar
  431. Kikra-Hanajiri R, Kawamura M, Maruyama T et al. (2009) Simultaneous analysis of mitragynine, 7-hydroxymitragynine and other alkaloids in the psychotropic plant „kratom“ (Mitragyna speciosa) by LC-ESI-MS. Forensic Toxicol 27(2):67–74CrossRefGoogle Scholar
  432. Killestein J, Hoogervorst ELJ, Reif M, Kalkers NF, Van Loenen AC et al (2002) Safety, tolerability and efficacy of orally administrated cannabinoids in MS. Neurol 58(9):1404–1407CrossRefGoogle Scholar
  433. Kintz P, Cirimele V (1997) Testing human blood for cannabis by GC/MS. Biomed Chromatogr 11:371–373CrossRefGoogle Scholar
  434. Kintz P, Cirimele V, Ludes B (2000) Testing for cannabis in saliva of impaired drivers. Blutalkohol 37:89–92Google Scholar
  435. Kintz P, Girond C (1997) Immunoassay responses of MBDB. J Anal Toxicol 21:589–590Google Scholar
  436. Kleiber D, Kovar KA (1998) Auswirkungen des Cannabiskonsums. Wissenschaftliche Verlagsgesellschaft, StuttgartGoogle Scholar
  437. Kleiner D (1992) Eine psychotische Episode mit Verkehrsunfall nach Cannabis-Konsum. Sucht 5:345–346Google Scholar
  438. Kleiner D, Stosberg K, Täschner K-L (1993) Erfahrungen mit Cannabiskonsumenten – Ergebnisse einer Umfrage bei Kliniken und Drogenberatungsstellen. Sucht 1:33–45Google Scholar
  439. Klette KL, Horn CK, Stout PR et al (2002) LC-MS Analysis of human urine specimens for 2-Oxo3-Hydroxy LSD: method validation for potential interferants and stability study of 2-Oxo-3Hydroxy LSD under various conditions. J Anal Toxicol 26(4):193–200CrossRefGoogle Scholar
  440. Klonoff H (1974) Marihuana and driving in real-life situations. Sci 32:317–323CrossRefGoogle Scholar
  441. Klonoff H (1983) Acute psychological effects of marihuana in man, including acute cognitive psychomotor and perceptual effects in driving. In: Fehr O’Brien K, Kalant H (eds) Cannabis and health hazards. Addiction Research Foundation, Toronto, pp 88–96Google Scholar
  442. Knapp H (1991) GABA ist an allem schuld. Suchtreport 5(2):28Google Scholar
  443. Knecht S (1962) Magische Pilze. Über die mexikanische Pilzzeremonie. Med Welt 35:1853–1859Google Scholar
  444. Kniesel M (1994) Nach der Entscheidung des BVerfG zur Strafbarkeit weicher Drogen. Anfang vom Ende der Drogenpolitik durch Strafrecht. ZRP 9:352–358Google Scholar
  445. Koch CAL (1864) Der Hanf. Allg Z Psychiatr 21:13–19Google Scholar
  446. Kolansky H, Moore WT (1971) Effects of marihuana on adolescents and young addults. JAMA 216:486–492CrossRefGoogle Scholar
  447. Konzett H (1981) Halluzinogene: LSD, Psilocybin und Mescalin. Dtsch Ärztebl 78:283–288Google Scholar
  448. Korte F et al (1965) THC-Carbonsäure, ein neuer Haschisch-Inhaltsstoff. Angew Chem 77:33–35Google Scholar
  449. Kouri EM, Pope HG, Lukas SE (1998) Changes in aggressive behavior during withdrawel from long-term marijuana use. Human Psychopharmacol 8:483–492Google Scholar
  450. Kovar K-A (1989) Designer-Drugs – Synthetische Suchtstoffe der 2. Generation. In: Kath. Sozialethische Arbeitsstelle (Hrsg.) Designer Drogen. Zum Gefährdungs-und Suchtpotential synthetischer Drogen. Hoheneck, HammGoogle Scholar
  451. Kovar K-A, Rösch C, Rupp A (1990) Synthetische Suchtstoffe der 2. Generation. 1. Mitt.: Amphetamine und andere Arylalkylamine. Pharm in unserer Zeit 19(3):99–107CrossRefGoogle Scholar
  452. Kraus L, Augustin R (2001) Repräsentativerhebung zum Gebrauch psychoaktiver Substanzen bei Erwachsenen in Deutschland 2000. Sucht 47(1):5–82Google Scholar
  453. Kronstrand R, Roman M, Thelander G, Eriksson A (2011) Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. J Analyt Toxicol 35(4):242–247CrossRefGoogle Scholar
  454. Krumdiek N (2008), Cannabis sativa L. und das Aufleben alter Vorurteile. NStZ 8:437–444Google Scholar
  455. Krumsiek L (1975) Haschischöl. Kriminalistik 3:124–128Google Scholar
  456. Kuehne ME (1964) The total synthesis of vincamine. J Am Chem Soc 86: 2946–2973CrossRefGoogle Scholar
  457. Kuehnle J, Mendelson JH, Davis DR, New PFJ (1977) Computer tomographic examination of heavy marihuana smokers. JAMA 237(12):1231–1232CrossRefGoogle Scholar
  458. Kumar S, Kunwar KB (1972) Chromosome abnormalities in cannabis addicts. J Assoc Phys India 19:193–195Google Scholar
  459. Kuntz M (1997) Mit Ecstasy auf der Suche nach dem verlorenen Glück – Du liebst alle und alle lieben Dich. Die Suchtarbeit mit Ecstasykonsumenten. Suchtreport 1:46–51Google Scholar
  460. Kutney JP, Brown RT, Piers E (1966) The absolute configuration of the Iboga alkaloids. Can J Chem 44:637–645CrossRefGoogle Scholar
  461. Kunert HJ (Hrsg.) (1999) Cannabis. Das unterschätzte Kraut. Ariadne, AachenGoogle Scholar
  462. Kvalseth TO (1977) Effects of marihuana on human reaction time and motor control. Percept Mot Skills 45:935–939CrossRefGoogle Scholar
  463. LaBarre W (1960) Twenty years of peyote studies. Curr Anthropol 1:45–60CrossRefGoogle Scholar
  464. LaBarre W (1972) Hallucinogens and the shamanic origin of religion. In: Furst P T (ed) Flesh of the Gods: The ritual use of hallucinogens. Praeger, New York, pp 36–49Google Scholar
  465. Lapoint J, James LP, Moran CL, Nelson LS, Hoffmann RS, Moran JH (2011a) Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Philadelphia) 49(8):760–764CrossRefGoogle Scholar
  466. Lapoint J, Nelson S (2011b) Synthetic Cannabinoids. The Newest, Almost Illicit Drug of Abuse. Emergency Medicine 43(2)_26–28Google Scholar
  467. La Valle S (1984) Hashish. Quarter Books, London New York MelbourneGoogle Scholar
  468. Law B (1984) Confirmation of cannabis use by the analysis of Δ9-THC metabolits in blood and urine by combined HPLC and RIA. J Anal Toxicol 8:19–22CrossRefGoogle Scholar
  469. Law B, Mason PA, Moffat AC et al (1984) Forensic Aspects of the Metabolism and Excretion of Cannabinoids Following Oral Ingestion of Cannabis Resin. J Pharm Pharmacol 36:289–294CrossRefGoogle Scholar
  470. Law FCP (1980) Metabolic disposition and potential toxicity of PCC in rats. Res Comm in Subst of Abuse 1(3):273Google Scholar
  471. Leaf RC, De Bold RC (1967) LSD, man and society. Wesleyan Univ Press, ConnecticutGoogle Scholar
  472. Leary T (1962) How to change behaviour. (Proceedings of XIV. International Congress on Applied Psychology, Copenhagen)Google Scholar
  473. Leary T (1964) The religious experience. Psychedelic Rev 3:30–42Google Scholar
  474. Leary T (1970) Politik der Ekstase. Wegner, HamburgGoogle Scholar
  475. Le Beau M (2000) Elevated GHB in citrate-buffered blood. J Anal Toxicol 24:283–384Google Scholar
  476. Le Beau MA, Miller ML, Levine B (2001) Effects of storage temperature on dendogenous GHB levels in urine. Forensic Sci Int 119:161–167CrossRefGoogle Scholar
  477. Le Beau MA, Montgomery MA, Miller ML, Burmeister SG (2000)Analysis of biofluids for gammahydroxybutyrate (GHB) and gamma-butyrolacetone (GBL) by headspace GC-FID and GC-MS. J Anal Toxicol 24:421–428CrossRefGoogle Scholar
  478. Leistenfels H von (oJ) Pilze: Speisepilz-Zucht Rauschpilz-Erkennung. Pieper & Die Grüne Kraft, Löhrbach (Grüner Zweig, Bd. 65)Google Scholar
  479. Lemberger L, Silberstein SD, Axelrod J, Kopin IJ (1970) Marihuana: studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. Sci 170:1320–1322CrossRefGoogle Scholar
  480. Lemberger L, Rubin A (1975) The physiologic disposition of marihuana in man. Life Sci 17:1637–1642CrossRefGoogle Scholar
  481. Leonhardt RW (1970) Haschischreport. Piper, MünchenGoogle Scholar
  482. Letcher A (2007) Shroom: A cultural history of the magic mushrooms. HarperCollinsGoogle Scholar
  483. Leuenburger H (1969) Zauberdrogen. Goverts, StuttgartGoogle Scholar
  484. Leuner H (1971) Halluzinogene in der Psychotherapie. Pharmakopsychiatry 4:333–351CrossRefGoogle Scholar
  485. Leuner H (1981) Halluzinogene. Huber, BernGoogle Scholar
  486. Levy JA, Munson AE, Harris LS, Dwewey WL (1975) Effects of delta-9-THC on the immune response of mice. Fed Proc 34:782–789Google Scholar
  487. Lewin L (1927) Phantastica – Die betäubenden und erregenden Genußmittel (Nachdruck 1981). Volksverlag, LindenGoogle Scholar
  488. Lewin L (1929) Banisteria Caapi. Stilke, BerlinGoogle Scholar
  489. Lewis EG, Peters BA, Dustman RE, Straight RC, Beck EC (1976) Sensory, perceptual, motor and cognitive functioning and subjective reports following oral admimistration of delta-9-THC. Psychopharmacologia (Berlin) 47:141–148CrossRefGoogle Scholar
  490. Li J, Stokes SA, Woeckener A (1998) A tale of novel intoxication: a review of the effects of gammahydroxybutyric acid with recommendations for management. Ann Emerg Med 31:729–736CrossRefGoogle Scholar
  491. Li Y, Husbands SM, Mahon MF et al (2007) Isolation and chemical modification of clerodane diterpenoids from Salvia species as potential agonists at the κ-opioid receptor. Chem Biodiversity 4:1586–1593CrossRefGoogle Scholar
  492. Liden CB, Lovejoy FH, Castello CE (1975) Phencyclidine – 9 Cases of Poisoning. JAMA 234(5):513–516CrossRefGoogle Scholar
  493. Lidz T, Rothenberg A (1970) Psychedelismus: Die Wiedergeburt des Dionysos. Psyche 24:359–374Google Scholar
  494. Liechti ME, Gamma A, Vollenweider FX (2001) Gender difference in the subjektive effects of MDMA. Psychopharmacol (Berlin) 154(2):161–168CrossRefGoogle Scholar
  495. Lin CY et al (2009) Toxicity and metabolism of methylnaphtalenes: camparison with naphthalene and 1-nitronaphtalene. Toxicol 260(1-3):16–27CrossRefGoogle Scholar
  496. Lindigkeil R, Boehme A, Eiserloh I, et al (2009) Spice: a never ending storie? Foren Scie Intern 191(1–3):58–63CrossRefGoogle Scholar
  497. Ling LH, Marcant C, Buckley NA, Prior M, Irvine RJ (2001) Poisning with the recreational drug paramethoxyamphetamine (“death”). Medical J of Australia 174:453–455Google Scholar
  498. Linszen DH, Dingemans PM, Lenior ME (1994) Cannabis Abuse and the Course of Recent-Onset Schizophrenic Disorders. Arch Gen Psychiatry 51:273–279CrossRefGoogle Scholar
  499. Lockwood TE (1979) The ethnobotany of brugmansia. J Ethnopharmacol 1:147–164CrossRefGoogle Scholar
  500. Löhrer F (1997) Biogene Suchtmittel. Ariadne, AachenGoogle Scholar
  501. Ludger E, Krueger K, Lindigkeit R, Schiebel HM, Beuerle T (2012) Synthetic cannabinoids in „sice-like“ herbal blends: first appearance of JWH-307 and recurrence of JWH-018 on the German market. For Sci Intern 222(1):216–222Google Scholar
  502. Ludlow FH (1981) Der Haschisch-Esser. Sphinx, BaselGoogle Scholar
  503. Luisada PV, Brown BJ (1976) Clinical Management of Phencyclidine Psychosis. Clin Toxicol 9(4):539–545CrossRefGoogle Scholar
  504. Lundberg GD, Gupta RC, Montgomery SH (1976) Phencyclidine: Patterns Seen in „Street Drug“ Analysis. Clin Toxicol 9(4):503–511CrossRefGoogle Scholar
  505. Lyon RA et al (1986) MDMA Stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacol 88:525–526CrossRefGoogle Scholar
  506. Madsen W (1955) Shamanism in Mexico. Southwest J Anthropol 2(1):48–57CrossRefGoogle Scholar
  507. Manallack DT, Davies JW, Beart PM, Saunders MR, Livingstone DJ (1993) Analysis oft he biological and molecular properties of phencyclidine-like compounds by chemometrics. Arzneimittelforschung 43(10):1092–1032Google Scholar
  508. Manden M, Skopp G, Mattern R, Aderjan R (2000) GC/MS-Bestimmung von THCCOOH im Serum: Vergleich verschiedenerAufarbeitungsmethoden und Einfluß von THCCOOH-Glucuronid. Blutalkohol 37:48–56Google Scholar
  509. Manno JE, Kiplinger GF, Haine SE, Bennett IF, Forney RB (1970) Comparative effects of smoking marihuana or placebo on human motor and mental performance. Clin Pharmacol Ther 11:808–815CrossRefGoogle Scholar
  510. Margolis JS, Clorfene R (1979) Der Grassgarten. Volksverlag, LindenGoogle Scholar
  511. Marijuana and Health (1980) 8th Annual Report to the US Congress from the Secretary of Health, Education and Welfare, Washington/DCGoogle Scholar
  512. Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE (1996) Reinforcing effects of certain serotonin-releasing amphetamine derivates. Pharmacol Biochem and Behavior 53(1):99–105CrossRefGoogle Scholar
  513. Marzell H (1964) Zauberpflanzen – Hexengetränke. Kosmos 241:47–55Google Scholar
  514. Marsicano G, Wotjak CT,Azad SC, Bisogno T, Rammes G et al (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418(6897):530–534CrossRefGoogle Scholar
  515. Mason AP, McBay AJ (1984) Ethanol, marijuana and other drugs in 600 drivers killed in single-vehicle crashes in North-Carolina 1978–1981. J Fornsic Sci 29:987–1026Google Scholar
  516. Mason AP, McBay AJ (1985) Cannabis. Pharmacology and Interpretation of effects. J Forensic Sci 30:615–631CrossRefGoogle Scholar
  517. Mattes RD, Shaw LM, Edling-Owens J et al (1993) Bypassing the first-pass effect for the therapeutic use of the cannabinoids. Pharmacol Biochem Behav 44:745–747CrossRefGoogle Scholar
  518. Maurer HH, Kreamer T, Springer D, Staack FR (2004) Chemistry, Pharmacology, Toxicology, and Hepatic Metabolism of designer DRugs of the Amphetamine (Ecstasy), Piperazine, and Pyrrolidinophenone Types, a Synopsis. Therapeutic Drug Monitor 26(2):127–131CrossRefGoogle Scholar
  519. McBay AJ (1985) Marijuana testing and litigation. J Forensic Sci 30:987–994Google Scholar
  520. McBay AJ (1988) Interpretation of Blood and Urine Cannabinoid Concentrations. J Forensic Sci 33:875–883CrossRefGoogle Scholar
  521. McBurney LJ, Bobbie BA, Sepp LA (1986) GC/MS and EMIT Analyses for Delta-9-Tetrahydrocannabinol Metabolites in Plasma and Urine of Human Subjects. J Anal Toxicol 10:55–64CrossRefGoogle Scholar
  522. McCann UB, Ridenour A, Graham Y, Ricaurte G (1994) Serotonin Neurotoxicity after MDMA (,Ecstasy‘): A controlled Study in Humans. Am Coll of Neuropsychopharmacol 2:129–138 9CrossRefGoogle Scholar
  523. McCullum NK, Shaw SM (1981) Chromatographic analysis for l9-tetrahydrocannabinol in blood and brain. J Anal Toxicol 5:148–149CrossRefGoogle Scholar
  524. McDonald PA, Martin CF, Woods DJ, Baker PB, Gough TA (1984) An analytical study of illicit lysergide. J Forensic Sci 29:120–130CrossRefGoogle Scholar
  525. McGee R, Williams S, Poulton R, Moffitt T (2000) Longitudinal study of cannabis use and mental health from adolescence to early adulthood. Addict 95:491–503CrossRefGoogle Scholar
  526. McGlothlin WS, Cohen S, McGlothlin M (1964) Short-term effects of LSD on anxiety, attitudes and performance. J Nerv Ment Dis 139: 266–273CrossRefGoogle Scholar
  527. McGlothlin WS, Cohen S, McGlothlin M (1970) Long lasting effects of LSD on normals. J Psychedelic Drugs 3:20–31CrossRefGoogle Scholar
  528. McLeary JA, Sypherd PS, Walkington DJ (1960) Antibiotic activity of an extract of peyote Lophophora williamsii (Lemaire) Coulter. Econ Bot 14:247–249CrossRefGoogle Scholar
  529. McNamara S (2008) 1-Benzylpiperazine (BZP) Abuse Amongst Attendees of the Drug Treatment Centre Bord. Irish Med J 102(6):191Google Scholar
  530. Meatherall RC, Warren RJ (1993) High urinary cannabinoids from a hashish body packer. J Anal Toxicol 17:439–440CrossRefGoogle Scholar
  531. Mechoulam R (1970) Marihuana chemistry. Sci 168:1159–1166CrossRefGoogle Scholar
  532. Mechoulam R (1973) Marihuana-Chemistry, pharmacology, metabolism and clinical effects. Academic Press, LondonGoogle Scholar
  533. Mechoulam R, Gaoni Y (1965) A total synthesis of d,1-delta-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 87:3273–3275CrossRefGoogle Scholar
  534. Mechoulam R et al (1988) Enantiomeric cannabinoids: stereospecifity of psychotropic activity. Experientia 44:762–764CrossRefGoogle Scholar
  535. Mechoulam R et al(1994) Search for endogenous ligands of the cannabinol receptor. Biochem Pharmacol 48:1537–1540CrossRefGoogle Scholar
  536. Mechoulam R, Panikasshvili D, Shohami E (2002) Cannabinoids and brain injury: therapeutic implications. Tends Mol Med 8:58–61CrossRefGoogle Scholar
  537. Mechoulam R (2005) Plant cannabinoids: a neglected pharmacological treasure trove. Brit J Pharmacol 146:913–915CrossRefGoogle Scholar
  538. Meck B (1981) Die Assassinen. Econ, Düsseldorf WienGoogle Scholar
  539. Melges FT, Tinklenberg JR, Hollister LE, Gillespie HK (1970) Marihuana and temporal disintegration. Sci 6:1118–1120CrossRefGoogle Scholar
  540. Mendelsohn JH (ed) (1974) The use of marihuana. Plenum, New YorkGoogle Scholar
  541. Mendelsohn JH (1987) Marijuana. In: Meltzer HY (ed) Psychopharmakology, Raven, New York, pp 60–67Google Scholar
  542. Merkus F et al (1971) TLC, GLC, MS of cannabidivarin, tetrahydrocannabivarin and cannabivarin. Acta Pharm Suec 8Google Scholar
  543. Merritt JC, Perry DD, Russell DN, Jones BF (1981) Topical delta-9-tetrahydrocannabinol and aqueous dynamics in glaucoma. J Clin Pharmacol 21(8–9 Suppl):467–471CrossRefGoogle Scholar
  544. Miller LL (ed) (1974) Marijuana – effects on human behavior. Academic Press, New York San Francisco LondonGoogle Scholar
  545. Miller LT, Cornett T, McFarland D (1978) Marijuana: an analysis of storage and retrieval deficits in memory with the technique of restricted reminding. Pharmacol Biochem Behav 8:327–332CrossRefGoogle Scholar
  546. Miller RA (1983) The magical and ritual use of herbs. Destiny, New YorkGoogle Scholar
  547. Miyajima M, Matsumoto T, Ito S (2008) 2C-T-4 intoxication: acute psychosis caused by a designer drug. Psychiatry and Clöinical Neurosciences 62(2):243CrossRefGoogle Scholar
  548. Moeller MR, Doerr G, Watts S (1992) Simultaneous quantitation of delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH) in serum by GC/MS using deuterated internal standards and its application to a smoking stydy and forensic cases. J Forensic Sci 37:969–983CrossRefGoogle Scholar
  549. Möller MR, Kauert G, Tönnes S, Schneider E, Theunissen EL, Ramaekers JG (2006) Leistungsverhalten und Toxikokinetik der Cannabinoide nach inhalativer Marihuanaaufnahme. Blutalkohol 43:361–375Google Scholar
  550. Möller-Nehring E, Luderer H-J (1997) Ist die Angst vor Ecstasy berechtigt? Fortschr Med 7:28–34Google Scholar
  551. Monte AP, Marona-Lewicka D, Cozzi NV, Nichols DE (1993) Synthesis and pharmacological examination of benzofuran, indan and tetralin analogues of 3,4-(methylenedioxy)amphetamine. J Med Chem 36(23):3700–3706CrossRefGoogle Scholar
  552. Monte AP, Waldman SR, Marona-Lewicka D et al (1997) Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivates. J Med Chem 40(19):2997–3008CrossRefGoogle Scholar
  553. Morgan MJ, McFie L, Fleetwood LH, Robinson JA (2002) Ecstasy (MDMA): Are the psychological probleme associated with ist use reversed by prolonged abstinence? Psychopharmacol 159:294–303CrossRefGoogle Scholar
  554. Morton JF (1981) Atlas of medical plants of middel america. Thomas, Springfield/ILGoogle Scholar
  555. Moskowitz H, Sharma S, McGlothlin WS (1972) Effetcs of marihuana upon peripheral vision as a function of the information processing demand in central vision. Percept Mot Skills 35:876–882CrossRefGoogle Scholar
  556. Moskowitz H, McGlothlin WS (1974) Effects of marihuana on auditory signal detection. Psychopharmacologia (Berlin) 48:137–145CrossRefGoogle Scholar
  557. Mowry M, Mosher M, Briner W (2003) Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A. J Psychactive Drugs 35:379–382CrossRefGoogle Scholar
  558. Munch JC (1974) Phencyclidine: Pharmakology and Toxicology. Bull Narc 26(4):9–17Google Scholar
  559. Munro TA (2006) The chemistry of Salvia divinorum. University Melbourne, MelbourneGoogle Scholar
  560. Mura P, Kintz P, Dumestre V, Raul S, Haue T (2005) THC can be detected in brain while absent in blood. J Anal Toxicol 29:842–843CrossRefGoogle Scholar
  561. Murray JB (1985) Marihuana’s Effects on Human Cognitive Functions, Psychomotor Functions, and Personality. J Gen Psychol 113:23–55CrossRefGoogle Scholar
  562. Mußhoff F, Graw M (2016) Dauerhafte Arzneimitteleinnahme – Frage nach Fahrsicherheit und der Fahreignung – Teil, Blutalkohol 53:333–346Google Scholar
  563. Myerhoff BG (1980) Der Peyote Kult. Trikont, MünchenGoogle Scholar
  564. Naef M, Russmann S, Petersen-Felix S et al (2004) Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. J Pharm Sci 93(5):1176–1184CrossRefGoogle Scholar
  565. Nahas GG (1972) Toxicology and pharmacology of cannabis sativa with special reference to delta-9-THC. Bull Narc 24:11–27Google Scholar
  566. Nahas GG (1974) Effects of cannabis and cannabinoids on cell replication and replication and DNA synthesis in man. J Pharmacol 5: 71–78Google Scholar
  567. Nahas GG (1975) Marihuana – Deceptive Weed. Raven Press, New YorkGoogle Scholar
  568. Nahas GG (1979) Keep off the grass. Pergamon, Oxford New YorkGoogle Scholar
  569. Nahas GG (1982) Hashish in Islam, 9th to 18th century. Bull NY Acad Med 58(9):814–831Google Scholar
  570. Nahas GG (ed) (1984) Marihuana in science and medicine. Raven, New YorkGoogle Scholar
  571. Nahas GG (1986) Cannabis: toxicological properties and epidemiological aspects. Med J Anst 145:82–87Google Scholar
  572. Nahas GG (1991) Es ist doch nur Marihuana. Suchtreport 5(2):18–27Google Scholar
  573. Nahas GG, Patton WDM (eds) (1979) Marihuana. Biological effects analysis, metabolism, cellular responses, reproduction and brain. Pergamon, OxfordGoogle Scholar
  574. Nahas GG, Sucia-Foca N, Armand J-P, Morishima A (1974) Inhibition of cellular mediated immunity in marihuana smokers. Sci 183: 419–420CrossRefGoogle Scholar
  575. Nahas GG, Desoize B, Hsu J, Morishima A, Srinvasan PR (1975) Inhibition of nucleic acid and poteins synthesis by natural cannabinoids and olivetol. (Abstract, IV. Int. Congress of Pharmacology, Helsinki, p 495)CrossRefGoogle Scholar
  576. Nahas GG, Patton WDM, Idänpään Heikkilä JE (eds) (1976) Marihuana: chemistry, biochemistry and cellular effects. Springer, New YorkGoogle Scholar
  577. Nahas GG, Latour Z (1992) The human toxicity of marihuana. Med J Anst 156(7):495–497Google Scholar
  578. Nakamura GR, Meeks RD, Stall WJ (1990) Solid-Phase Extraction, Identification and Quantitation of 11-nor-Delta-9-Tetrahydrocannabinol-9-carboxylic Acid. J Forensic Sci 35:792–796CrossRefGoogle Scholar
  579. Negrete JC (1973) Psychological adverse effects of cannabis smoking. A tentative classification. Can Med Assoc J 108:195–196Google Scholar
  580. Negrete JC, Knapp WP (1996) The effects of cannabis use on the clinical condition of schizophrenics. NIDA Res Monogr 67:321–327Google Scholar
  581. Neu RL, Powes HO, King S, Gardner LI (1969) Cannabis and chromosomes. Lancet I:675CrossRefGoogle Scholar
  582. Neumeyer JL, Shagoury L (1971) Chemistry and pharmacology of marijuana. J Pharm Sci 60:1433– 1451CrossRefGoogle Scholar
  583. Neuninger H (1988) Zur Bewertung von inländischen Cannabis-Produkten. Österr RichterZ 66:127– 130Google Scholar
  584. Nichols DE, Hoffmann AJ, Oberlender RA et al (1986) Derivats of 1-(1,3-Benzodioxol-5-ylbutanamine): Representatives of a Novel Therapeutic Class. J Med Chem 29(10):2009–2015CrossRefGoogle Scholar
  585. Nichols DE, Johnson MP, Oberlender R (1991) 5-iodo-2-aminoindan, a nonneurotoxic analog of para-iodoamphetamine. Pharmacol Biochem and Behavior 38:135–139CrossRefGoogle Scholar
  586. Nichols WW, Miller RC, Heneen W, Bradt C, Hollister L, Kanter S (1974) Cytogenetic studies on human subjects receiving marihuana and delta-9-tetrahydrocannabinol. Mutat Res 26:413–417CrossRefGoogle Scholar
  587. Niedbala RS, Kardos KW, Fritch DF, Kardos S, Fries T, Waga J (2001) Detection of Marijuana Use by Oral Fluid and Urine Analysis Following Single-Dose Administration of Smoked and Oral Marijuana. J Anal Toxicol 25:289–303CrossRefGoogle Scholar
  588. Niedbala RS, Kardos K, Salamone S, Fritch D, Bronsgeest M, Cone EJ (2004) Passive Cannabis Smoke Exposure and Oral Fluid Testing. J Anal Toxicol 28:546–552CrossRefGoogle Scholar
  589. Nolte F (2002) Cannabis im Straßenverkehr – Zur Inszenierung und Dramaturgie eines gesellschaftlichen „Problems“. Blutalkohol 39 (Suppl. 1):17–20Google Scholar
  590. Novotny M, Lee MC, Keast D (1976) A possible chemical basis for the higher mutagenicity of marihuana smoke as compared to tobacco smoke. Experientia 32:280–282CrossRefGoogle Scholar
  591. Nowlan R, Cohen S (1977) Tolerance to marihuana: heart rate and subjective „high“. Clin Pharmacol Ther 22:550–555CrossRefGoogle Scholar
  592. Noyes R (1975) The analgesic properties of delta-9-THC and codeine. Clin Pharmacol Ther 18:84–89CrossRefGoogle Scholar
  593. Obrocki J, Buchert R,Vaterlein O, Thomasius R et al (1999) Ecstasy-long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry 175:186–188CrossRefGoogle Scholar
  594. O’Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME (1988) Methylendioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8:2788–2803CrossRefGoogle Scholar
  595. Ohlsson A, Lindgren JE, Wahlen A et al (1980) Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28:409–416CrossRefGoogle Scholar
  596. Ohlsson A, Lindgren JE, Wahlen A et al (1982) Single dose kinetics of deuterium labelled delta-1tetrahydrocannabinol in heavy and light cannabis users. Biomed Mass Spectrom 9:6–10CrossRefGoogle Scholar
  597. Okun MS, Boothby LA, Bartfield RB, Doering PL (2001) GHB: an important pharmacological and clinical update. J Pharm Sci 4:167–175Google Scholar
  598. Olson RW (2000) Absinthe and g-aminobutyric acid receptors. Proc Natl Acad Sci USA 97:4417– 4418CrossRefGoogle Scholar
  599. Olvedi U (1972) LSD-Report. Suhrkamp, Frankfurt am MainGoogle Scholar
  600. Orzechowski G (1969) Halluzinogene Drogen, Med Welt 16:955–963Google Scholar
  601. Oss OT, Oeric ON (1976) Psilocybin, magic mushrooms grower’s guide. And/Or Press, BerkeleyGoogle Scholar
  602. Ott J (1976) Hallucinogenic plants of North America. Wingbow, Berkeley/CAGoogle Scholar
  603. Ott J, Bigwood J (eds) (1978) Teonanacatl: Hallucinogenic mushroom of North America. Madrona, Seattle/WAGoogle Scholar
  604. Pace HD, Davis A, Borgen LA (1971) Teratogenesia and marihuana. Ann NYAcad Sci 191:123–128CrossRefGoogle Scholar
  605. Pahnke W (1963) Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness. Master’s thesis Univ of HarvardGoogle Scholar
  606. Parrott AC, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacol (Berlin) 139(3):261–268CrossRefGoogle Scholar
  607. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W (2002) Cannabi use and mental health in young people: cohort study. Br Med J 325:1195–1198CrossRefGoogle Scholar
  608. Patzak J, Marcus A, Goldhausen S (2006) Cannabis – wirklich eine harmlose Droge? NStZ 5:259– 266Google Scholar
  609. Patzak J, Goldhausen S (2007) Der aktuelle Wirkstoffgehalt von Cannabis. NStZ 4:195–198Google Scholar
  610. Patzak J, Goldhausen S (2011) Der aktuelle Wirkstoffgehalt von Cannabis. NStZ 2:76–78Google Scholar
  611. Paulzen A, Gründer G (2008) Toxic psychosis after intake of the hallucinogen salvinorin A. J Clin Psych 69:1501–1502CrossRefGoogle Scholar
  612. Payne RJ, Brand SN (1975) The toxicity of intravenously used marihuana. JAMA 233:351–354CrossRefGoogle Scholar
  613. Pearlson GD (1981) Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. Johns Hopkins medical journal 148:25–33Google Scholar
  614. Peeke SC, Jones RT, Stone GC (1976) Effects of practice an marihuana – induced changes in reaction time. Psychopharmacol 48: 159–163CrossRefGoogle Scholar
  615. Peel HW, Perrigo BJ (1981) Detection of cannabinoids in blood using EMIT. J Anal Toxicol 5:165–167CrossRefGoogle Scholar
  616. Perez-Reyes M, Owens SM, DiGuiseppe S (1981) The clinical pharmacology and dynamics of marihuana cigarette smoking. J Clin Pharmacol 21:201s–207sCrossRefGoogle Scholar
  617. Perez-Reyes M, DiGuiseppe S, Davis KH et al (1982) Comparisation of effects of marihuana cigarettes of three different potencies. Clin Pharmacol Ther 31:617–624CrossRefGoogle Scholar
  618. Peronka S, Newman M, Harris H (1988) Subjective Effects of DOM in Recreational Users. Neuropsychopharmacol 1:273–277Google Scholar
  619. Perontka SJ (ed) (1990) Ecstasy, the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Khiver Academic Publishers, BostonCrossRefGoogle Scholar
  620. Personne M, Hulten P (2008) Bromo-Dragonfly, a life threatening designer drug. Clin Toxicol 46:379–380Google Scholar
  621. Pertwee RG (2001) Cannabinoid receptors and pain. Progress Neurobiol 63(5):569–611CrossRefGoogle Scholar
  622. Pertwee RG (2005) Pharmacological actions of cannabinoids, In: Pertwee RG (ed) Cannabinoids. Handbook of Experimental Pharmacology Bd 168. Springer, Berlin/HeidelbergGoogle Scholar
  623. Petersen BH, Graham J, Lembeger L (1976) Marihuana, tetrahydrocannabinol and T-cell function. Life Sci 19:395–400CrossRefGoogle Scholar
  624. Petersen RC (ed) (1977) Marihuana research findings. NIDA Res Monogr 14:205–218Google Scholar
  625. Petersen RC (ed) (1980) Marijuana research findings. NIDA Res Monogr 31:69–85Google Scholar
  626. Petersen RC, Stillman RC (1978) Phencyclidine (PCP) abuse: An appraisal. NIDA Res Monogr 21:168–175Google Scholar
  627. Petro DJ, Ellenberger C (1981) Treatment of human spasticity with delta-9-THC. J Clin Pharmacol 21:413–416CrossRefGoogle Scholar
  628. Petrzilka T (1971) Chemie synthetischer Hanf-Derivate. Bull Schweiz Akad Med Wiss 27:22–27Google Scholar
  629. Petrzilka T, Haefliger W, Sikemeier G, Ohloff G, Eschenmoser A (1967) Synthese und Chiralität des (-)-Cannabidiols. Helv Chim Acta 50:719–723CrossRefGoogle Scholar
  630. Peuckert W-E (1960) Hexensalben. Med Monatsspiegel 9:169–174Google Scholar
  631. Piggee C (2009) Investigating a not so natural high. Analyt Chem 81(9):3205–3207CrossRefGoogle Scholar
  632. Piomelli D, Giuffrida A, Calingnano A, de Fonseca FR (2000) The endocannabinoid system as a target for the therapeutic drugs. Trends Pharmacol Sci 21:218–224CrossRefGoogle Scholar
  633. Poehlke T (1995) MDMA – Droge oder Medikament? Westfäl Ärztebl 8:16–19Google Scholar
  634. Pope HG (2002) Cannabis, cognition and residual confounding. JAMA 287(9):1172–1174CrossRefGoogle Scholar
  635. Pope HG, Gruber AJ, Hudon JI, Huestis MA, Yurgelun-Todd D (2001) Neuropsychological performance in long-term Cannabis users. Arch Gen Psychiatry 58:909–915CrossRefGoogle Scholar
  636. Pope HH Jr (1969) Tabernanthe iboga – an African narcotic plant of social importance. Econ Bot 23:174–184CrossRefGoogle Scholar
  637. Porter AC, Felder CC (2001) The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 90(1):45–60CrossRefGoogle Scholar
  638. Przekop P, Lee T (2009) Persistent psychosis assiciated with Salvia divinorum use. Am J Psych 166:832CrossRefGoogle Scholar
  639. Priemer F, Grappmaier A, Ruby M et al (1999) Pupillenverhalten unter akutem THC-Einfluß. Blutalkohol 32:84–98Google Scholar
  640. Prisinzano TE (2005) Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sci 78:527–531CrossRefGoogle Scholar
  641. Rabes M, Harm W (Hrsg.) (1997) XTC und XXL: Ecstasy-Wirkungen, Risiken, Vorbeugungsmöglichkeiten und Jugendkultur. Rowohlt, ReinbekGoogle Scholar
  642. Rätsch C (1995) Die Grüne Fee: Absinth in der Schweiz. Jahrbuch für Ethnomedizin und Bewusstseinsforschung 4:285–287Google Scholar
  643. Rätsch C (1998) Enzyklopädie der psychoaktiven Pflanzen: Botanik, Ethnopharmakologie und Anwendung. AT VerlagGoogle Scholar
  644. Raffauf RF, Flagler MB (1960) Alkaloids of the apocynaceae. Econ Bot 14:37–46CrossRefGoogle Scholar
  645. Rakete G, Flüsmeier U (1997) Der Konsum von Ecstasy. Eine empirische Studie zu Mustern und psychosozialen Effekten des Ecstasykonsums. Bundeszentrale für gesundheitliche Aufklärung, Köln.Google Scholar
  646. Ramaekers JG, Kauert G, Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR (2006) High-Potency Marijuana Impairs Executive Function and Inhibitory Motor Control. Neuropsychopharmacol 31:2296–2303Google Scholar
  647. Randall T (1992) „Rave“ Scene, Ecstasy Use, Leap Atlantic. JAMA 268:1506–1509CrossRefGoogle Scholar
  648. von Ranke-Graves R (1985) Griechische Mythologie. Rowohlt, ReinbekGoogle Scholar
  649. Ray R, Prabhu GG, Mohan D, Nath LM, Neki JS (1978) Cannabis use. The association between chronic abuse and cognitive functions. Drug Alcohol Depend 3:365–368CrossRefGoogle Scholar
  650. Rayner R (1979) Pilze erkennen – leicht gemacht. Franck’sche Verlagsbuchhandlung, StuttgartGoogle Scholar
  651. Reed A, Kane W (1972) Phencyclidine (PCP). J Psychedelic Drugs 5(1): 8–12CrossRefGoogle Scholar
  652. Reeve VC, Grant JD, Robertson W et al (1983a) Plasma concentration of delta-9tetrahydrocannabinol and impaired motor function. Drug Alcohol Depend 11:176–175CrossRefGoogle Scholar
  653. Reeve VC, Robertson WB, Grant J (1983b) Hemolyzed blood and serum levels of Δ9-THC: Effects on the performance of roadside sobriety tests. J Fornesic Sci 28:963–971Google Scholar
  654. Remschmidt H (1972) Haschisch und LSD. Physische und psychische Wirkungen. Med Klin 67:706–716, 781–786Google Scholar
  655. Renault PF, Schuster CR, Heinrich R, Freeman DX (1971) Marihuana: Standartized smoking administration and dose effects on heart rate in humans. Sci 174:589–591CrossRefGoogle Scholar
  656. Reynolds PC (1976) Clinical and Forensic Experiences with Phencyclidine. Clin Toxicol 9(4):547– 552CrossRefGoogle Scholar
  657. Ricklin F (1989) Cannabis: harmloses Rauschgift? Schweiz Med Wochenschr 119:1173–1176Google Scholar
  658. Rivier L, Lindgren J-E (1972) Ayahuasca – South American hallucinogenic drink: ethnobotanical and chemical investigations. Econ Bot 24:100–129Google Scholar
  659. Robinson TE, Castaneda E, Wislaw IQ (1993) Effects of cortical serotonin depletion induced by 3,4methylendioxymethamphetamine (MDMA) on behavior, before and after additional cholinergic blockade. Neuropsychopharmacol 8(1):77–85CrossRefGoogle Scholar
  660. Robson O (2001) Therapeutic aspects of cannabis and cannabinoids. Br J Psychiat 178:107–115CrossRefGoogle Scholar
  661. Rösch C et al (1990) Synthetische Suchtstoffe der 2. Generation. 2. Mitt.: Analytik der Arylalkylamine. Pharm in unserer Zeit 19(5): 211–221CrossRefGoogle Scholar
  662. Rodin E, Domino E, Porzak J (1970) The marijuana induced social high – Neurological and electroencephalographic concomitants. JAMA 213:1300–1202CrossRefGoogle Scholar
  663. Rosenthal E (1984) Marijuana beer. And/Or Press, BerkeleyGoogle Scholar
  664. Rumpf HJ, Hoch E, Thomasius R, Havemann-Reinecke U (2015) Stellungnahme zur Legalisierungsdebatte des nicht-medizinischen Cannabiskonsums. Blutalkohol 52:329–333Google Scholar
  665. Safford WE (1916) Identity of cohoba, the narcotic snuff of ancient Haiti. J Wash Acad Sci 6:548–562Google Scholar
  666. Sahihi A (1989) Designer-Drogen: die neue Gefahr. Beltz, Weinheim BaselGoogle Scholar
  667. Sahihi A (1991) Designer-Drogen: Zwischen Hölle und Paradies. Suchtreport 5(1):42–47Google Scholar
  668. Sainsbury PD, Kicman AT, Archer PP, King LA, Braithwaite RA (2011) Aminoindanes – the next wave of “legal highs”? Drug Testing and Analysis 3:479–482CrossRefGoogle Scholar
  669. Sallan SE, Zinberg NE, Frei E (1975) Antiemetic effect of delta-9-THC in patients receiving cancer chemotherapy. N Eng J Med 293: 795–797CrossRefGoogle Scholar
  670. Sankar DVS (1975) LSD – A total study. PJD Publications, Westbury/NYGoogle Scholar
  671. Sankar DVS, Roszy PW, Geisler A (1969) Chromosome breakage in children treated with LSD-25 und UML-491. Compr Psychiatry 10: 406–410CrossRefGoogle Scholar
  672. Saunders N (1994) „Ecstasy“. Bilger, ZürichGoogle Scholar
  673. Saxton JE (1956) The indole alkaloids excluding harmine and strychnine. Q Rev 10:108–112CrossRefGoogle Scholar
  674. Schaefer N, Peters B, Bregel D et al. (2013) A fatal case involving several synthetic cannabinoids. Toxichem Krimtech 80 (Special issue):248Google Scholar
  675. Schäper J, Thiemt S, Wende M (2011) Assessment of supposedly legal designer drugs und “legal highs” according to the Medical Products Act (AMG). Toxichem Krimtech 78 (Sonderausgabe)Google Scholar
  676. Scherer S (1996) Cannabis als Genußmittel? ZRP 5:187–191Google Scholar
  677. Schleifer H (1973) Sacred narcotic plants of the New World Indians. Hafner, New YorkGoogle Scholar
  678. Schmidt D (1970) Halluzinogene aus Pflanzen. Naturwiss Rundschau 23:5Google Scholar
  679. Schmidt MD, Schmidt MS, Butelman ER et al (2005) Pharmacokinetics of the plant-derived κ-opioid hallucinogen Salvinorin A in nonhuman primates. Synapse 58:208–210CrossRefGoogle Scholar
  680. Schmidt MM, Sharma A, Schifano F, Feinmann C (2011) „Legal highs“ on the net-Evaluation of UK-based Wbsites, products and product information. Foren Science Intern 206(1):92–97CrossRefGoogle Scholar
  681. Schmidt P, Scheer N, Berghaus G (1995) Cannabiskonsum und Fahrtüchtigkeit. Kriminalistik 4:241–246Google Scholar
  682. Schmiechen R et al (1986) Carbolines – A new class of compounds with high affinity for benzodiazepine receptors. Sonderdruck: IXth Int. Symposium on Medicinal Chemistry, BerlinGoogle Scholar
  683. Schmitt G, Herbold M, Aderjan R (1999) Berechung der Nachweis-, der Erfassungs-und der Bestimmungsgrenze von Tetrahydrocannabinol (THC) im Serum. Blutalkohol 36:362–370Google Scholar
  684. Schönhofer PS (1973) Die Pharmakologie der Cannabis-Wirkstoffe. Arzneimittelforsch 23:50–55Google Scholar
  685. Schoeppner H (Hrsg.) (1994) Gammahydroxybuttersäure als Neurotransmitter. Medizin im Blickpunkt. Innovations-Verlags-Gesellschaft, Seeheim JugenheimGoogle Scholar
  686. Schreiber LH (1997) Das Urteil des BGH zu Ecstasy. NJW 12:777–779Google Scholar
  687. Schreiber LH (2005) Die Bewertung von THC-Spuren bei Verurteilung wegen Drogenfahrt. NJW 15:1026–1027Google Scholar
  688. Schrenk T von (1999) Internistische Komplikationen nach Ecstasy. Dtsch Ärztebl 96:A–347–352Google Scholar
  689. Schultes RE (1941) A contribution to our knowledge of rivea corymbosa, the narcotic ololiuqui of the Aztecs. Harvard Botanical Museum, Cambrigde/MAGoogle Scholar
  690. Schultes RE (1965) Ein halbes Jahrhundert amerikanischer Ethnobotanik der Halluzinogene. Planta med 13:125–129CrossRefGoogle Scholar
  691. Schultes RE (1969) Hallucinogens of plant origin. Sci 163: 245–254CrossRefGoogle Scholar
  692. Schultes RE (1969/1970) The plant kingdom and hallucinogens. Bull Narc 21:3–16, 22:25–53Google Scholar
  693. Schultes RE (1970a) The botanical and chemical distribution of hallucinogens. Ann Rec Plant Physiol 21:571–590CrossRefGoogle Scholar
  694. Schultes RE (1970b) Botany and chemistry of cannabis. Churchill, LondonGoogle Scholar
  695. Schultes RE (1972) An overview of hallucinogens in the western hemisphere. In: Furst PT (ed) Flesh of the Gods: The ritual uses of hallucinogens. Praeger, New York, pp 3–54Google Scholar
  696. Schultes RE (1976) Hallucinogenic plants. Golden Press, New YorkGoogle Scholar
  697. Schultes RE, Hofmann A (1980) The botany and chemistry of hallucinogens. Thomas, Springfield/ILGoogle Scholar
  698. Schultes RE, Hofmann A (1995) Pflanzen der Götter. Die magischen Kräfte der Rausch-und Giftgewächse. AT, AarauGoogle Scholar
  699. Schultz OE, Haffner C (1958) Zur Kenntnis eines sedativen Wirkstoffes aus dem deutschen Faserhanf. Arch Pharm (Berlin) 291:20–24CrossRefGoogle Scholar
  700. Schulz V (1984) Behandlung des Ergotismus. Fortschr Med 8:189–190Google Scholar
  701. Schurz J (1970) Vom Bilsenkraut zum LSD. Frank’sche Verlagsbuchhandlung, StuttgartGoogle Scholar
  702. Schuster P, Wittchen H-U (1996) Ecstasy-und Halluzinogengebrauch bei Jugendlichen. Gibt es eine Zunahme? Verhaltenstherapie 6:222–223CrossRefGoogle Scholar
  703. Schwarz CJ (1968) The complications of LSD: a review of the literature. J Nerv Ment Dis 146:174–186CrossRefGoogle Scholar
  704. Seely K et al. (2012) Spice drugs are more than harmless herbal blends: A review of pharmacology and toxicology of synthetic cannabinoids. Progress in Neuro-Psychopharm and Biological Psycgiatry 39:234–243CrossRefGoogle Scholar
  705. Seywright A, Torrance HJ, Wylie M, McKeown DA, Lowe DJ, Stevenson R (2016) Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA. Clin Toxicol 54(8):632–637CrossRefGoogle Scholar
  706. Sharma S, Moskowitz H (1972) Effect of marihuana on the visual autokinetic phenomenon. Percept Mot Skills 35:891–894CrossRefGoogle Scholar
  707. Sheridan J, Butler R, Wilkins C, Russell B (2007) Legal piperazine-containing party pills–anew trend in substance misuse. Drug Alcohol Rew 26(3):335–343CrossRefGoogle Scholar
  708. Shanks KG, Behnick GS (2016) Death after Use of the Synthetic Cannabinoid 5F-AMB. Forensic Sci Int 262:e21–e24CrossRefGoogle Scholar
  709. Shulgin AT, MacLean DE (1976) Illicit Synthesis of Phencyclidine (PCP) and several of its Analogs. Clin Toxicol 9(4):553–560CrossRefGoogle Scholar
  710. Shulgin AT, Shulgin A (1991) TIHKAL (Tryptamines I have known and loved): A chemical love story. Transform Press, Berkeley, CAGoogle Scholar
  711. Shulgin AT, Shulgin A (1995) PIHKAL: A chemical love story. Transform Press, BerkeleyGoogle Scholar
  712. Shulgin AT, Shulgin A (1997) THIKAL: The continuation. Transform Press, BerkeleyGoogle Scholar
  713. Siebert DJ (1994) Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 43:53–56CrossRefGoogle Scholar
  714. Sigrist T, Germann U, Sutter K (1998) Intoxikation mit Stechapfelgift (Scopolamin). Kriminalistik 3:219–221Google Scholar
  715. Silverman J (1968) Shamans and acute schizophrenia. Am Anthropol 69: 21–31CrossRefGoogle Scholar
  716. Simon NG, Mattick RP (2002) The impact of regular ecstasy use on memory functions. Addict 97:1523–1529CrossRefGoogle Scholar
  717. Sklerov J, Levibne B, Moore KA, King T, Fowler D (2005) A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J Analyt Toxicol 29(8):838–841CrossRefGoogle Scholar
  718. Skopp G, Pötsch L (2001) Zur Passivexposition bei der Beurteilung niedriger Cannabinoidkonzentrationen im Blut und Urin. Arch Kriminol 207(5–6):137–147Google Scholar
  719. Skopp G, Dettling A, Pötsch L, Schmitt G, Haffne HAT (2003) Begleitstoffprofile Absinth-haltiger Bitterspirituosen. Blutalkohol 40:287–293Google Scholar
  720. Skopp G, Richter B, Pötsch L (2003) Cannabinoidbefunde im Serum 24 bis 48 Stunden nach Rauschkonsum. Arch Kriminol 212:83–95Google Scholar
  721. Skopp G, Pötsch L (2008) Cannabinoid concentrations in spot serum samples 24-48 hours after discontinuation of cannabis smoking. J Anal Toxicol 32:160–164CrossRefGoogle Scholar
  722. Skopp G (2012) Cannabis. In: Haffner HT, Skopp G, Graw M (Hrsg.) Begutachtung im Verkehrsrecht. Springer, HeidelbergGoogle Scholar
  723. Smith MV (1981) Psychedelic chemistry. Loompanics Unlimited Mason/USA (Nachdruck des 1973 in Rip Off Press erschienenen Werkes)Google Scholar
  724. Smith NT (2002) A review of the published literature into cannabis withdrawal symptoms in human users. Addict 97:621–632CrossRefGoogle Scholar
  725. Smith PB et al (1994) The Pharmacological Activity of Anandamide, a Putative Endogenous Cannabinoid, in Mice. J Pharmacol 270:219–220Google Scholar
  726. Smith RN, Robinson K (1985) Body fluid levels of lysergide (LSD). Forensic Sci Int 28:229–237CrossRefGoogle Scholar
  727. Snyder SH (1967) STP: a new halluzinogenic drug. Sci 158:669–712CrossRefGoogle Scholar
  728. Solomons E, Sam J (1973) 2-aminoindans of pharmacological interest. J Medicinal Chem 16(12):1330–1333CrossRefGoogle Scholar
  729. Solowij NS, Stephens RS, Roffmann RA, Babor T, Kadden R et al (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287(9):1123–1131CrossRefGoogle Scholar
  730. Soueif MI (1976) Differential association between chronic cannabis use and brain function deficits. Ann NY Acad Sci 282:323–343CrossRefGoogle Scholar
  731. de Souza E, Battaglia G, Insel T (1990) Neurotoxic Effects of MDMA on Brain Serotonin Neurons: Evidence from Neurochemical and Radioligand Binding Studies. Ann NY Acad Sci 6:682–698CrossRefGoogle Scholar
  732. Soyka M et al (1993) Zur Phänomenologie einer ketamininduzierten Psychose. Sucht 39(5):327–331Google Scholar
  733. Spanos LJ, Yamamoto BK (1989) Acute and subchronic effects of methylenedioxymethamphetamine (MDMA) on locomotion and serotonin Syndrome behaviour in rat. Pharmacol Biochem Behav 32:835–840CrossRefGoogle Scholar
  734. Stafford P (1980) Enzyklopädie der psychedelischen Drogen. Volksverlag, LindenGoogle Scholar
  735. Stahl E et al (1978) Rauschgiftpilze mit LSD? Arch Krim 162(1/2):23Google Scholar
  736. Stanton MD, Mintz J, Franklin RM (1976) Drug flashbacks. II: Some additional findings. Int J Addict 11:53–69CrossRefGoogle Scholar
  737. Starks M (1979) Marijuana potency. And/Or Press, BerkeleyGoogle Scholar
  738. Steckel R (oJ) Bewußtseinserweiternde Drogen. Haschisch – Marihuana – LSD – Meskalin – STP(DOM) – Psilocybin – Ololiuqui. Edition VoltaireGoogle Scholar
  739. Stefanis C, Dornbush R, Fink M (1977) Hashish-studies of long-term use. Raven, New YorkGoogle Scholar
  740. Steinecke H, Hein C, Stein U, Klein A, Hentschel H (2002) Intoxikation mit Liquid Ecstasy. Rechtsmedizin 1:375–377Google Scholar
  741. Stenchever MA, Kunysz TJ, Allen MA (1974) Chromosome breakage in users of marihuana. Am J Obstet Gynecol 118:106–113CrossRefGoogle Scholar
  742. Stevens A (2002) Cannabis und Cannabinoide als Medizin. Sucht 48:329–335CrossRefGoogle Scholar
  743. Stillwell ME (2002) Drug-facilitated sexual assault involving gamma-hydroxybutyric acid. J Forensic Sci 47:1133–1134CrossRefGoogle Scholar
  744. Stoll WA (1947) Lysergsäureamid, ein Phantastikum aus der Mutterkorngruppe. Schweiz Arch Neurol Psychiatr 60:279–323Google Scholar
  745. Stoll WA (1952) Recent investigations on ergot alkaloids. Fortschr Chem Org Naturst 9:114–119Google Scholar
  746. Stosberg K, Lösch H (1987) Haschisch-Spätfolgen. Suchtreport 5:13–16Google Scholar
  747. Stowe BB (1959) Occurence and metabolism of simple indoles in plants. Fortschr Chem Org Naturst 17:248–252Google Scholar
  748. Strang J, Arnold WN, Peters T (1999) Absinthe: what’s your poison? Brit Med J 319:1590–1592CrossRefGoogle Scholar
  749. Stringaris MG (1972) Die Haschischsucht. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  750. Stromberg VL (1954) The Isolation of bufotenin from Piptadenia peregrina. J Am Chem Soc 76:170– 171CrossRefGoogle Scholar
  751. Sullivan AT, Twitchett PJ, Fletcher SM, Moffat AC (1978) The fate of LSD in the body: forensic considerations. J Forensic Sci 18: 89–98CrossRefGoogle Scholar
  752. Svrcek M (1979) Der Kosmos-Pilzführer. Frank’sche Verlagsbuchhandlung, StuttgartGoogle Scholar
  753. Swatek R (1984) Marijuana use: Persistence and urinary elimination. J Substance Abuse Treatment 1:265–270CrossRefGoogle Scholar
  754. Tancer ME, Johanson CE (2003) Reinforcing, subjective, and physiological effects of MDMA in humans: a comparisation with d-amphetamine and mCPP. Drug Alcohol Dependence 72(1):33–44CrossRefGoogle Scholar
  755. Täschner K-L (1980) Haschisch für alle? Hess Ärztebl 7 (Sonderdruck)Google Scholar
  756. Täschner K-L (1981) Das Haschischproblem aus klinischer Sicht. Dtsch Ärztebl 78:126–129Google Scholar
  757. Täschner K-L (1983) Zur Psychopathologie und Differentialprognose sogenannter Cannabispsychosen. Fortschr Neurol Psychiatr 51: 235–248CrossRefGoogle Scholar
  758. Täschner K-L (1986) Das Cannabisproblem – Haschisch und seine Wirkungen. Deutscher Ärzte-Verlag, KölnGoogle Scholar
  759. Täschner K-L, Wanke K (1975) Zur Frage der toxischen Psychose am Beispiel der sog. LSD-Psychose. Fortschr Med 31:1515–1518, 1542Google Scholar
  760. Täschner K-L, Frießen DH (1989) Verkehrstauglichkeit bei Rauschgiftkonsumenten unter besonderer Berücksichtigung des Cannabismißbrauchs. Suchtgefahren 35:253–262 (Sonderdruck)Google Scholar
  761. Tarshis MS (1972) The LSD controversy – an overview. Thomas, Springfield/ILGoogle Scholar
  762. Tashkin DP (1987) Marijuana-Bronchitis. Am Rev Resp Dis 135:209Google Scholar
  763. Tashkin DP, Simmons M, Clark V (1988) Effect of habitual smoking of marijuana alone and with tobacco on nonspecific airways hyperreacticity. J Psychoactive Drugs 20:21–25CrossRefGoogle Scholar
  764. Taylor FM (1988) Marijuana as a potential respiratory tract carcinogen: a retrospective analysis of a community hospital population. South Med J 81:1213–1216CrossRefGoogle Scholar
  765. Taylor WI (1966) Indole alkaloids, an introduction to the enamine chemistry of natural products. Pergamon, New YorkGoogle Scholar
  766. Teske J, Weller J-P, Fieguth A, Thämel T, Schulz Y, Tröger HD (2010) Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalene-1-yl(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B 878(27):2659–2883CrossRefGoogle Scholar
  767. Teitelbaum DT, Wingeleth DC (1977) Diagnosis and management of recreational mescaline poising. J Anal Toxicol 1:36–37CrossRefGoogle Scholar
  768. Tennant FS, Groesbeck CJ (1972) Psychiatric effects of Hashish. Arch Gen Psychiatry 27:133–136CrossRefGoogle Scholar
  769. Tennant FS, Preble M, Prendergast TJ, Ventry P (1971) Medical manifestations associated with Hashish. JAMA 216:1965–1969CrossRefGoogle Scholar
  770. Tenscher E, Lindenquist U (1994) Biogene Gifte. Gustav-FischerGoogle Scholar
  771. Teuchert-Noodt G, Bagorda F (2002) Drogen-induzierte Destabilisierung psycho-kognitiver Leistungen als Gefahr für den Straßenverkehr – Wie sich Ecstasy und andere Drogen in das Gehirn einschreiben, und die Frage nach den Chancen einer Therapie. Blutalkohol 39 (Suppl. 1):21–31Google Scholar
  772. Thamm BG (1987a) Alltagsdroge Haschisch. Suchtreport 1(4):2–7Google Scholar
  773. Thamm BG (1987b) Synthetische Drogen. Suchtreport 1(3):52–54Google Scholar
  774. Thamm BG (1990) Pflanzen der Götter. Suchtreport 4(3):48–57Google Scholar
  775. Theale JD, Forman EF, King LJ (1975) The development of a radioimmunassay for cannabinoids in blood and in urine. J Pharm Pharmacol 27:465–472CrossRefGoogle Scholar
  776. Thomas WR, Holt PG, Keast D (1974) Recovery of immune system after cigarette smoking. Nat 248:358–359CrossRefGoogle Scholar
  777. Thomasius R (Hrsg.) (1999) Ecstasy-Wirkungen, Risiken, Interventionen. Ein Leitfaden für Klinik und Praxis. Enke, StuttgartGoogle Scholar
  778. Thomasius R (Hrsg.) (2000) Ecstasy: Eine Studie zu gesundheitlichen und psychosozialen Folgen des Missbrauchs. Wiss Verlagsges, StuttgartGoogle Scholar
  779. Thomasius R et al (1997) MDMA („Ecstasy“)-Konsum – ein Überblick zu psychiatrischen und medizinischen Folgen. Fortschr Neurol Psychiatr 65:49–61 (Sonderdruck)CrossRefGoogle Scholar
  780. Thomasius R, Jarchow C (1997) „Ecstasy“: Psychotrope Effecte, Komplikationen, Folgewirkungen. Dtsch Ärztebl 94A:372–376 (Sonderdruck)Google Scholar
  781. Thomasius R, Petersen KU, Küstner U, Wartberg L, Zeichner D (2004) Cannabis als Medikament – eine Nutzen/Risiko-Abwägung. Blutalkohol 9:383–400Google Scholar
  782. Tönnes SW, Kauert GF (2002) Pharmakokinetische Simulation der Plasmakonzentration von Δ9 -tetrahydrocannabinol (THC) nach oraler Aufnahme von Hanföl. Blutalkohol 39:237–243Google Scholar
  783. Tönnes S, Auwärter V, Knoche A, Skopp G (2016) Stand der wissenschaftlichen Erkenntnisse zur Feststellung einer mangelnden Trennung von Cannabiskonsum und Fahren anhand der Konzentration von Tetrahydrocannabinol (THC) im Blutserum. Blutalkohol 53:409–414Google Scholar
  784. Tong TG, Benowitz NL, Becker CE, Forni PJ, Boerner U (1975) Phencyclidine Poisoning. JAMA 234(5):572–573CrossRefGoogle Scholar
  785. Tossmann HP (1997) Ecstasykonsummuster, Konsumkontexte und Komplikationen. Ergebnisse der Ecstasy-Infoline. Sucht 43:121–129Google Scholar
  786. Tossmann HP, Boldt S, Tensil MD (2001) The use of drugs within the techno party scene in European metropolitan cities. Eur Addict Res 7(1):2–23CrossRefGoogle Scholar
  787. Treffert DA (1978) Marihuana use in schizophrenia: a clear hazard. Am J Psychiatry 135:1213–1215CrossRefGoogle Scholar
  788. Tsujikawa K, Yamamuso T, Muwayama K et al. (2014) Thermal degradation of a new synthetic cannabinoid QUPIC during analysis by gaschromatography-massspectrometry. Foren Toxicol 32:201–207CrossRefGoogle Scholar
  789. Uchiyama N et al (2009) Identification of a cannabimimetic indole as a designer drug in a herbal product. Foren Toxicol 27:61–66CrossRefGoogle Scholar
  790. Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2013) URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int 227:21–32CrossRefGoogle Scholar
  791. Ungerleider JT et al (1968) The „bad trip“ – the etiology of the adverse LSD reaction. Am J Psychiatry 124:1483–1490CrossRefGoogle Scholar
  792. United Kingdom, Advisory Council on the Misuse of Drugs (ACMD) (2012) Methoxetamine Report. Home OfficeGoogle Scholar
  793. United Nations Office on Drugs and Crime (2011) Synthetic cannabinoids in herbal products. WienGoogle Scholar
  794. United Nations Office on Drugs and Crime (2012) UNODC questionnaire on new psychoactive substances, submitted by Member States and a network of drug analysis laboratoriesGoogle Scholar
  795. United Nations Office on Drugs and Crime (2013) The challenge of new psychoactive substances. A Report from the Global SMART ProgrammeGoogle Scholar
  796. Vierth G (1967) Psycho-pathologische Syndrome nach Haschischgenuß. MMW 1:522–528Google Scholar
  797. Vogel R, Matthiessen W, Bruckner O, Alexander M (1981) Lungenkomplikationen bei Rauschgiftsucht. Prax Pneumol 35:988–991Google Scholar
  798. Van Peteghen C, Heyndrickx A, Van Zelle W (1980) GLC-mass spectral determination of mescaline in plasma of rabbits after intravenous injection. J Pharm Sci 69:118–120CrossRefGoogle Scholar
  799. Völger G (Hrsg.) (1982) Rausch und Realität, Drogen im Kulturvergleich, Bde 1–3. Rowolth, Reinbek (Materialienband zur Ausstellung des Rautenstrauch-Joest-Museums für Völkerkunde der Stadt Köln 1981, Teil 1 und 2)Google Scholar
  800. Vogt DD (1981)Absinthium: A Nineteenth-Century Drug ofAbuse. J Ethnopharmacol 4(3):337–342CrossRefGoogle Scholar
  801. Vogt DD, Montagne M (1982) Absinthe: Behind the Emerald Mask. Intern J Addictions 17 (6):1015–1029CrossRefGoogle Scholar
  802. Vollenweider FX (1992) Die Anwendung von Psychotomimetika in der Schizophrenieforschung unter Berücksichtigung der Ketamin/PCP-Modellpsychose. Sucht 38:298–409Google Scholar
  803. Wall ME, Perez-Reyes M (1981) The metabolism of delta-9-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 21: 178s–189sGoogle Scholar
  804. Wall ME, Sadler BM, Brine D et al (1983) Metabolism, disposition, and kinetics of delta-9tetrahydrocannabinol in men and women. Clin Pharmacol Ther 34(3):352–363CrossRefGoogle Scholar
  805. Waser P (1971) Pharmakologische Wirkungsspektren von Halluzinogenen. Bull Schweiz Akad Med Wiss 27:39–57Google Scholar
  806. Wasson RG (1959) The hallucinogenic mushrooms of Mexiko. Acad Sci, New YorkGoogle Scholar
  807. Wasson RG (1962) The hallucinogenic mushrooms of Mexiko and psilocybin: a bibliography. Bot Mus Leafl Harv Univ 20:20–73Google Scholar
  808. Wasson RG (1968) Soma. Divine mushroom of immortality. Harcourt Brace Jovanovich, New YorkGoogle Scholar
  809. Wasson RG, Hofman A, Ruck CAP (1978) The road to Eleusis: Unveiling the secrets of the mysteries. Harcourt Brace Jovanovich, New YorkGoogle Scholar
  810. Wasson VP, Wasson RG (1957) Mushrooms. Russia and history. Pantheon, New YorkGoogle Scholar
  811. Wax RH, Wax ML (1962) The magical world view. J Sci Study Rel 1:179–188CrossRefGoogle Scholar
  812. Wehner HD, Wildemann H, Köhling R (2006) Quantitative Pharmakokinetik der passiven THC-Aufnahme. Blutalkohol 43:349–360Google Scholar
  813. Weidig B (2013) Zur Strafbarkeit von „Legal Highs“, Blutalkohol 50:57–73Google Scholar
  814. Weidmann H, Taeschler M, Konzett H (1958) Zur Pharmakologie von Psilocybin, einem Wirkstoff aus Psilocybe mexicana Heim. Experentia 14:378–379CrossRefGoogle Scholar
  815. Weissman A, Milne GM, Melvin LS Jr (1982) Cannabimimetic activtiy from CP-47, 497, a derivate of 3-phenylcyclohexanol. J Pharmacol Exp Ther 223:516–523Google Scholar
  816. Willis PG, Pavlova OA, Chefer SI, Vaupel DB, Mukhin AG, Horti AG (2005) Synthesis and Structure-Activity Relationship of a Novel Series of Aminoindoles with Potential for Imaging the Neuronal Cannabinoid Receptor by Positron Emission Tomography. J Med Chem 48(18):5813–5822CrossRefGoogle Scholar
  817. Wells B (1974) Psychedelic drugs. Penguin, BaltimoreGoogle Scholar
  818. Westphal F, Junge T, Rosner P, Sonnichsen F, Schuster F (2009) Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: a designer drug with a pyrrolidinophenone structure. Foren Sci Intern 190:1–8CrossRefGoogle Scholar
  819. Whites SC, Brin SC, Janicki BW (1975) Mitogen-induced blastogenic responses of lymphocytes from marihuana smokers. Sci 188: 71–72CrossRefGoogle Scholar
  820. Whiting JD, Manders WW (1982) Confirmation of Tetrahydrocannabinol Metabolite in Urine by Gas Chromatography. J Anal Toxicol 6:49–52CrossRefGoogle Scholar
  821. Widmann M, Agurell S, Ehrnbo M, Jones G (1974) Binding of (+)-Δ1-and (-)-Δ1tetrahydrocannabinols and (-)-7-hydroxytetrahydrocannabinol in blood cells and plasma proteins in man. J Pharm Pharmacol 26:914–916CrossRefGoogle Scholar
  822. Wiley JL, Compton DR, Dai D, Lainton JAH, Phillips M, Huffman JW, Martin BR (1998) Structure-Activity Relationships of Indole- and Pyrrole-Derived Cannabinoids. J Pharmacol Ther 285(3):995–1004Google Scholar
  823. Wiley JL, Marusich JA, Huffmann JW (2013a) Moving around the molecule: Relationship between chemical structure and in vivo activity of synthetic cannabinoid. Life Sci 97(1):55–63CrossRefGoogle Scholar
  824. Wiley JL, Marusich JA, Lefever TW, Grabenauer M, Mooere KN, Thomas BF (2013b) Cannabinoids in Disguise, Δ9-Tetrahydrocannabinol-like Effects of Tetramethylcoclypropyl Ketone Indoles. Neuropharmacol 75:145–154CrossRefGoogle Scholar
  825. Williams EG, Himmelsbach CK, Wikler A, Ruble D C, Lloyd BJ Jr (1964) Studies on marijuana and parahexyl compund. Public Health Rep 61:1059–1084CrossRefGoogle Scholar
  826. Williams PL, Moffat AC (1980) Identification in human urine of delta-9-tetrahydrocannabinol-11-oc acid glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol 32:445–448CrossRefGoogle Scholar
  827. Winterfeldt E (1971) Neuere Aspekte in der Chemie der Indolalkaloide. Chimia 25:394–396Google Scholar
  828. Winterfeldt E (1974) Stereoselektive Totalsynthese von Indolalkaloiden. Fortschr Chem Org Naturst 31:469–472Google Scholar
  829. Woggon B (1974) Haschisch – Konsum und Wirkung. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  830. Wood DM, Button J, Lidder S et al (2008) Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and 1-benzylpiperazine (BZP). J Medical Toxicol 4(4):254–257CrossRefGoogle Scholar
  831. Yago KB, Pitts FN Jr, Burgoyne RW et al (1981) The urban epidemie of phencyclidine (PCP) use. J Clin Psychiatry 42:193–196Google Scholar
  832. Yeatman DT, Reid K (2003) A study of urinary endogenous gamma-hydroxybutyrate (GHB) levels. J Anal Toxicol 27:40–42CrossRefGoogle Scholar
  833. Yesavage JA et al (1985) Carry-over effects of marihuana intoxication on aircraft pilot performance. Am J Psychiatry 142:1325–1329CrossRefGoogle Scholar
  834. Zellweger H, McDonald JS, Abbo G (1967) Is isoergicacid diethylamide a teratogen? Lancet 7525:1066–1068CrossRefGoogle Scholar
  835. Zhang Y, Butelman ER, Schlussman SD et al (2005) Effects of the plant-derived hallucinogen salvinorinA on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonst actions at kappa opioid receptors. Psychopharmacol 179:551–558CrossRefGoogle Scholar
  836. Zimmermann AM, Ray AY (1980) Influence of cannabinoids on somatic cells in vivo. Pharmacol 21:277–287CrossRefGoogle Scholar
  837. Zimmermann S, Zimmermann AM, Cameron IL, Laurence HL (1977) Delta-9-tetrahydrocannabinol, cannabidiol and cannabinol effects on the immune response of mice. Pharmacol 15:10–23CrossRefGoogle Scholar
  838. Zimmermann US et al (2009) Withdrawal phenomena and a dependence syndrome after the consumption of „Spice Gold“. Dt Ärztebl Intern 106(27):464–467Google Scholar
  839. Zinck R, Möller D (Hrsg.) (1998) Designer-Drogen vom Amphetamin-Typ „Ecstasy“. Abbott, WiesbadenGoogle Scholar
  840. Zingg C, Bovens M (2000) „Ecstasy“-Tabletten und deren kriminalpolizeiliches Auswertungspotenzial. Kriminalistik 12:833–838Google Scholar
  841. Zschockelt A (1986) Die „nicht geringe Menge“ Cannabis – Problematik der THC-Bestimmung. MDR 6:457–459Google Scholar
  842. Züger V (1974) Eine neue Form von Haschisch. Haschisch-Öl. Kriminalistik 18(3):129Google Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Thomas Geschwinde
    • 1
  1. 1.HanauDeutschland

Personalised recommendations